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The discovery of microRNA (miRNA) is one of the major sci-
entific breakthroughs in recent years and has revolutionized 
current cell biology and medical science. miRNAs are small 
(19∼25nt) noncoding RNA molecules that post-transcrip-
tionally regulate gene expression by targeting the 3’ un-
translated region (3’UTR) of specific messenger RNAs 
(mRNAs) for degradation of translation repression. Genetic 
ablation of the miRNA machinery, as well as loss or degrada-
tion of certain individual miRNAs, severely compromises im-
mune development and response, and can lead to immune 
disorders. Several sophisticated regulatory mechanisms are 
used to maintain immune homeostasis. Regulatory T (Treg) 
cells are essential for maintaining peripheral tolerance, pre-
venting autoimmune diseases and limiting chronic in-
flammatory diseases. Recent publications have provided 
compelling evidence that miRNAs are highly expressed in 
T r e g  c e l l s ,  t h a t  t h e  e x p r e s s i o n  o f  F o x p 3  i s  c o n t r o l l e d  b y  
miRNAs and that a range of miRNAs are involved in the regu-
lation of immunity. A large number of studies have reported 
links between alterations of miRNA homeostasis and patho-
logical conditions such as cancer, cardiovascular disease and 
diabetes, as well as psychiatric and neurological diseases. 
Although it is still unclear how miRNA controls Treg cell de-
velopment and function, recent studies certainly indicate that 
this topic will be the subject of further research. The specific 
circulating miRNA species may also be useful for the diag-
nosis, classification, prognosis of diseases and prediction of 
the therapeutic response. An explosive literature has fo-
cussed on the role of miRNA. In this review, I briefly summa-
rize the current studies about the role of miRNAs in Treg cells 
and in the regulation of the innate and adaptive immune 
response. I also review the explosive current studies about 
clinical application of miRNA.
[Immune Network 2011;11(1):11-41]
INTRODUCTION
R e g u l a t o r y  T  ( T r e g )  c e l l s  a r e  a  d i s t i n c t  l y m p h o c y t e  l i n e a g e  
endowed with inhibitory properties that affect the activation 
of the immune system. Treg cells (also called suppressor T 
cells)  were first  described  in the  early 1970s  in  a  series  of 
papers concerning thymic suppressor cells that could inhibit 
cell-mediated immunity in many different in vivo models (1-7) 
and that were characterized by the expression of CD25 and 
the Treg-specific forkhead/winged helix transcription factor 3 
(Foxp3), which is required for their development and func-
tion (8-12). These cells can inhibit activation of other T cells 
and are needed for protection against autoimmune diseases 
and prevent rejection of allogeneic transplants (6,7,13-15). In 
humans,  mutations  in  Foxp3  result  in  an  autoimmune  syn-
drome  termed  IPEX  (immunodysregulation,  polyendocrino-
pathy  enteropathy,  X-linked  syndrome),  an  X-linked  im-
munodeficiency syndrome characterized by insulin-dependent 
diabetes, thyroiditis, massive T cell infiltration in multiple or-
gans,  and  chronic  wasting  (8,9,16).  However,  immunor-
egulatory function of Treg cells may hinder the induction of 
immune  responses  against  cancer  and  infectious  agents 
(14,17,18). Counteracting Treg cell activity can evoke effec-
tive antitumor immunity (18-24), and inhibition of Treg cell 
f u n c t i o n  i n  p a t i e n t s  w i t h  c a n c e r  i s  a n  e s s e n t i a l  s t e p  t o  i m-
prove  the  efficacy  of  antitumor  therapies,  especially  those MicroRNAs in Regulatory T Cells and Immune Response
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based in immunotherapeutic approaches (11,16,18,21,23-30).
  MicroRNAs (miRNAs) are small (19-22-nt) noncoding RNA 
molecules that are single-stranded in the functional form and 
derived from hairpin-structured precursors (31). Unlike their 
small size, they play an important role in the regulation of 
gene  expression  at the  post-transcriptional  level.  After  their 
discovery in Caenorhabditis elegans (32-34), there have been 
a  large  number  of  studies  identifying  miRNA  in  animals, 
plants, and viruses. Since the initial observation, more than 
7 0 0  m i R N A s  h a v e  b e e n  i d e n t i f i e d  i n  m a m m a l i a n  c e l l s  a n d  
have been shown to play important roles in human develop-
ment, cellular differentiation and homeostasis, adaptation to 
the environment, oncogenesis, and host cell interactions with 
pathogens (35-41). Since miRNAs act as key regulators in a 
wide variety of biological processes, it is now apparent that 
abnormal miRNA expression is a common feature of various 
diseases (42-54). Recently, more miRNAs have been reported 
to be involved in the regulation of immune systems, demon-
strating that miRNAs modulate many aspects of the immune 
responses such as differentiation, proliferation, cell fate deter-
mination, function of immune cells, and cytokine responses, 
as well as the intracellular signaling pathways (55-69). They 
function  by  directly  binding  to  the  3’  untranslated  regions 
(3’UTRs) of specific target mRNA, leading to the repression 
of  protein  expression  and  the  production  of  target  mRNA 
degradation.  So  far,  over  700  different  miRNAs  have  been 
identified in the human genome (35,36). Each miRNA could 
have the potential to repress the expression of many, perhaps 
hundreds, of target genes. More than 100 different miRNAs 
are expressed by cells of the immune system and they have 
the potential to broadly influence the molecular pathways that 
control the development and function of innate and adaptive 
immune responses (35,57,58,65-67,70,71). The expression of 
miRNA is also markedly dysregulated in cancers of immuno-
logical  origin,  in  which  they  are  thought  to  have  tu-
mor-suppressive or tumor-promoting activities depending on 
the nature of their specific target mRNA (35,49,72-83). Now, 
miRNA  studies  are  resolving  some  unsolved  issues  in 
immunology. Recent studies have shown that miRNAs have 
unique expression profiles in cells of the innate and adaptive 
immune systems, and have pivotal roles in the regulation of 
both  cell  development  and  function  (18,35,55,67,71,84-88). 
Furthermore, when miRNAs are aberrantly expressed they can 
contribute  to  pathological  conditions  involving  the  immune 
system, such as cancer and autoimmunity (35,43,68,89). They 
have also been shown to be useful as diagnostic and prog-
nostic  indicators  of  disease  type  and  severity  (35,82,90-95).
  It is, therefore, not surprising that these novel class of cel-
lular regulators have been shown to be involved in regulation 
of various processes for cell fate determination, such as cell 
cycle,  proliferation,  apoptosis,  differentiation  and  develop-
ment of nervous, skeletal and cardiac muscle tissues and hae-
matopoietic stem cells (96,97). The de-regulation of such en-
dogenous  and  epigenetic  transcriptional  networks  involving 
miRNA  may  be  relevant  to  disease  pathogenesis  (43,89,96, 
98,99).  Recent  studies  have  also  implicated  aberrant  ex-
pression of specific miRNAs in a broad spectrum of human 
diseases,  including  diabetes  (50,54),  cardiovascular  disease 
(47,100) cancer (42,72-79,83,101-104), endotoxin shock (105), 
neurodegenerative  diseases,  including  Alzheimer’s  disease, 
Parkinson’s disease, spinocerebellar ataxia, Huntington’s dis-
ease (45,106), psychiatric disease, such as schizophrenia, bi-
polar disorder and autism (43), rheumatic diseases (89,107- 
109), ethanol addiction (48), renal disease (50), endometriosis 
(51),  asthma  (52),  and  prion  disease  (53).
  The first indication that miRNA might regulate the immune 
responses was a report in 2004 showing selective expression 
of miR-142a, miR-181a and mir-223 in immune cells (38). In 
t h i s  s t u d y ,  m i R - 1 8 1 a  w a s  l o c a l i z e d  i n  B - l y m p h o c y t e s ,  m i R -  
142a in B-lymphocytes and myeloid cells whilst miR-223 was 
confined to myeloid cells (38). Since this initial observation, 
miRNAs have been implicated in the regulation of maturation, 
proliferation,  differentiation,  and  activation  of  immune  cells 
(65).
Treg CELLS
CD4＋ T  cells  orchestrate  diverse  modes  of  immune  re-
sponses by differentiating into distinct helper subsets, charac-
terized by unique patterns of cytokine secretion (110). There 
are three subsets: Th1 cells, which secrete the signature cyto-
kine interferon-gamma (IFN-γ), Th2 cells, which secrete the 
signature cytokine interleukin (IL)-4 and Th17 cells, which se-
crete  IL-17  (110).  Dysregulated  differentiation  of  CD4＋ T 
cells can lead to defects in the development of pathogen-spe-
cific  immune  response  and  can  also  result  in  lympho-
cyte-mediated  disease  (110).
    There are at least three recognized subsets of CD4＋ Treg 
cells involved in the negative regulation of immune response 
(16,111-115). Type 1 Treg (Tγ 1) cells are induced in the 
periphery and suppress T cell proliferation through the pro-
duction of IL-10 and transforming growth factor-β (TGF-β), MicroRNAs in Regulatory T Cells and Immune Response
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and do not have a unique cell marker, but are identified by 
their production of IL-10 and not pro-inflammatory cytokines. 
T helper 3 (Th3) cells are a regulatory T cell population that 
originates in the periphery and mediates suppression through 
the secretion of TGF-β. Importantly, CD4＋CD25＋Foxp3＋ 
Treg cells are classical Treg cells. Depletion of these cells has 
attracted much attention in recent years (11,16,22,23,28,116, 
117).  CD4＋CD25＋Foxp3＋Treg  cells,  according  to  their 
sources, can be divided into two classes: naturally occurring 
T r e g  ( n T r e g )  c e l l s  a n d  a d a p t i v e  o r  i n d u c i b l e  T r e g  ( i T r e g )  
cells. nTreg cells are generated in the thymus during develop-
ment of T cells (112,118). These cells, which constitute 5∼
10% of the total lymphocytes, enter the peripheral circulation 
and are widely distributed in peripheral reservoir lymph no-
des and spleen (12,112,113,115,117). Thymus-derived CD4＋
CD25＋Foxp3＋Treg cells are stable with respect to retaining 
regulatory  function  and  Foxp3  expression  in  the  periphery 
(117). On the contrary, iTreg cells are developed in the pe-
riphery from naive T cells or nTreg cells under the influence 
of various inductive signals, most importantly TGF-β or IL-10 
(27,111,112,119).  Treg  cells  are  primarily  characterized  by 
CD4＋Foxp3＋ or CD4＋CD25＋Foxp3＋ T cells, and Foxp3 
has been considered as a master regulatory transcription fac-
tor  for  Treg  cells  (10-12,15,116).  Recently,  Taylor  and 
Llewelyn  reported  that  superantigen  (staphylococcal  enter-
otoxin A or streptococcal pyrogenic exotoxin A) can induce 
Treg  cells  in  human  peripheral  blood  mononuclear  cells 
(PBMCs)  and  approximately  2%  of  circulating  T  cells  are 
nTreg cells (120). Thornton et al. (121) reported that in both 
mouse and human, approximately 70% of peripheral Foxp3＋ 
Treg cells express the transcription factor Helios. Interestin-
gly, they found that Foxp3 cells generated in the thymus all 
co-expressed  Helios,  whereas  Treg  cells  generated  in  vitro 
from conventional peripheral T cells with anti-CD3 and an-
ti-CD28 antibody stimulation in the presence of IL-2 and TGF-
β1 do not express Helios. This, they suggested, could mean 
that approximately 70% of Foxp3＋ Treg cells in the periph-
ery are thymically-generated, and 30% are derived from pe-
ripheral  conversion  of  conventional  T  cells.  These  results 
demonstrate that Helios is potentially a specific marker of thy-
mic-derived  Treg  cells  and  raises  the  possibility  that  a  sig-
nificant  percentage  of  Foxp3＋ Treg  cells  are  generated 
extrathymically. It has also been reported that Foxp3＋ Treg 
c e l l s  a l s o  g e n e r a t e d  o u t s i d e  t h e  t h y m u s  u n d e r  a  v a r i e t y  o f  
conditions  (12,27,122).
    Very  currently,  various  research  groups  have  reported 
many  interesting  findings.  Kerdiles  et  al.  reported  that  T 
cell-specific  loss  of  Foxo1  resulted  in  exocrine  pancreatitis, 
hind  limb  paralysis,  multi-organ  lymphocyte  infiltration,  an-
ti-nuclear  antibodies,  and  expanded  germinal  centers,  and 
that Foxo transcription factors are essential for the develop-
ment and function of Foxp3-expressing Treg cells by control-
ling the expression of genes associated with Treg cell func-
tion  (123).  Procaccini  et  al.  reported  that  the  anergic  state 
of Treg cells depends on the elevated activity of the mamma-
lian target of rapamycin (mTOR) pathway induced by leptin: 
transient  inhibition  of  mTOR  with  rapamycin,  before  T  cell 
receptor stimulation, made Treg cells highly proliferative in 
the absence of exogenous IL-2 (124). Treg cells from aged 
mice  are  more  resistant  to  apoptosis  than  Treg  cells  from 
young mice and, notably, aged Treg cells exhibit decreased 
expression of the proapoptotic molecule Bim compared with 
Treg cells from young mice (125). Casares et al. reported that 
a  15-mer  synthetic  peptide  designated  P60  enters  the  cells, 
inhibits Foxp3 nuclear translocation, and reduces its ability to 
suppress  the  transcription  factors  nuclear  factor-kappa  B 
(NF-kB) and nuclear factor of activated T-cells (NFAT) (29). 
They also reported that P60 induces protection against tumor 
implantation and, similarly, improves the antiviral efficacy of 
a recombinant adenovirus expressing NS3 protein from hep-
atitis C virus. The data indicate that functional inhibition of 
Treg cells by the Foxp3-inhibitory peptide P60 may enhance 
antitumor  and  antiviral  immunotherapies  (29).
    Interestingly,  systemically  applied  glucocorticosteroids 
(GCSs) endow epidermal Langerhans cells with Treg-promot-
ing properties, which have shed new light on the mechanisms 
of  GCS-mediated  immunosuppression  (126).  Eller  et  al.  re-
ported that IL-9 production by Treg cells recruits mast cells, 
providing  the  first  direct  in  vivo  evidence  that  the  neph-
roprotective, anti-inflammatory effects of Treg cells critically 
depend  on  IL-9-mediated  attraction  of  mast  cells  into  kid-
ney-draining lymph nodes (127). Interestingly, the vitamin D 
analog,  TX527,  promotes  a  human  CD4＋CD25
highCD127
low 
Treg cell profile (128). T-cell activation and function require 
a structural engagement of antigen-presenting cells and these 
cell  contacts  are  characterized  by  two  distinct  dynamics  in 
vivo: transient contacts resulting from promigratory junctions 
called  immunological  kinapses  or  prolonged  contacts  from 
stable  junctions  called  immunological  synapses  (IS). 
Comparison of the ability of Treg cells and Th cells to form 
IS  on  supported  planar  bilayers  revealed  that  human  Treg 
cells form more stable IS than do Th (129). Synapse stabiliza-MicroRNAs in Regulatory T Cells and Immune Response
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Figure 1. miRNA biosynthesis path-
way. miRNA are initially transcribed
by RNA polymerase II as long 
primary miRNAs (pri-miRNA). Pri- 
miRNAs are cleaved in the nucleus 
by the RNase III enzyme Drosa- 
DGCR8 complex, liberating the 
stem loop or pre-miRNA. The pro-
tein Exportin-5 escorts the pre- 
miRNA to the cytoplasm, where a 
second RNAse enzyme, Dicer 
cleves the pre-miRNA to produce a 
miRNA duplex. From this miRNA/ 
miRNA* duplex, the miRNAs strand
is loaded iinto the RNA-induced 
silencing complex (RISC), and the 
miRNA* strand is destroyed. The 
final step in miRNA maturation is 
the loading of the miRNA strand 
into an Argonaute protein and 
destruction of the miRNA* strand. 
Translational repression of targeted 
mRNAs or mRNA degradation by 
RISC may occur within the P-body 
(For the details, see Text).
tion may enhance Treg function, as suggested by the recent 
evidence that IS play an important role in Treg effects medi-
ated  through  dendritic c e l l s  ( D C s )  ( 1 2 9 ) .
    Humans  harbor  nearly  100  trillion  intestinal  bacteria  that 
are essential for health. Millions of years of co-evolution have 
molded this human-microorganism interplay into a symbiotic 
relationship,  in  which  gut  bacteria  make  essential  con-
tributions to human nutrient metabolism and in return occupy 
a  nutrient-rich  environment  (110).
    There is also evidence that Treg cells are induced by in-
testinal bacteria or their molecular products, such as the poly-
saccharide A carbohydrates expressed by Bacillus fragilis and 
the  non-culturable  Clostridia-related  segmented  filamentous 
bacteria, and that there is spontaneous intestinal inflammation 
in  mice  with  specific  deficiencies  in  regulatory  cytokines 
(such as IL-10 and TGF-β) or in factors that determine Treg 
cell thymic selection (such as autophagy-related gene; 5), dif-
ferentiation  and/or  function  (such  as  Foxp3  or  αVβ8  in-
tegrin) (110). These findings clearly indicate that Treg cells 
play an important role in immune adaptations that maintain 
intestinal  homeostasis  with  intestinal  microorganisms.
miRNA BIOGENESIS
Small RNAs can be classified into different groups based on 
their origin or the components to which they coupled (31,39, 
130,131). These small RNA groups include miRNAs, small-in-
terfering RNAs (siRNAs), trans-acting siRNAs (tasiRNAs), small- 
scan  RNAs  (scnRNAs),  repeat-associated  siRNAs  (rasiRNAs), 
and Piwi-interating RNAs (piRNAs). siRNAs are the products 
of long, Dicer-processed, double-stranded (ds) RNAs that si-
lence  genes  by  cleaving  their  target  mRNAs  (31,36,130). 
Regardless of the type and size, small non-coding RNAs share 
one unifying function in cellular physiology - epigenetic regu-
lation  of  gene  expression  (35,37).
    The  process  of  miRNA  biogenesis  and  target  mRNA  re-
pression have been extensively studied and reviewed (31,37, 
48,55,96,132). Human miRNA are present in introns of coding 
genes  and  introns  and  exons  of  noncoding  transcripts.  To 
generate mature miRNA, primary miRNAs (pri-miRNAs) from 
long primary transcripts go through a series of endonucleo-
lytic steps. Pri-miRNAs containing a 5’7-methylguanosine cap 
and  3’  poly  (A)  tail  are  transcribed  by  RNA  polymerase  II, 
w h e r e a s  o t h e r s  a r e  t r a n s c r i b e d  b y  R N A  p o l y m e r a s e  I I I  
(130,133). The pri-RNAs are then recognized and cleaved by 
the Drosha-DGCR8 (DiGeorge syndrome critical region 8 ho-
mologue) microprocessor complex to yield an approximately 
70nt intermediate with the typical stem-loop hairpin structure, 
precursor  miRNAs  (pre-miRNAs),  in  the  nucleus  (134,135). 
After transported to the cytoplasm by the RanGTP-dependent 
dsRNA-binding protein Exportin 5 (135), the pre-miRNAs are 
further processed into an approximately 22nt double-stranded MicroRNAs in Regulatory T Cells and Immune Response
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Figure 2. Possible effects of aberrant 
expression of miRNA in immune 
response (For the details, see Text).
miRNA duplex by the cytoplasmic RNAase III enzyme Dicer 
(136). One strand of this miRNA duplex, which is designated 
as the guide strand, is incorporated into a large protein com-
plex, miRNA-induced silencing complex (miRISC), formed by 
Dicer, TRBP (human immunodeficiency virus 1-transactivating 
response RNA-binding protein, a dsRNA-binding domain pro-
tein)  and  Ago2  (Argonaute  protein-2),  to  yield  the  mature 
miRNA. miRISC is then transported by importin 8 to its cog-
n a t e  m R N A ,  l e a d i n g  t o  r e p r e s s i o n  o f  t h e  t a r g e t .  F i n a l l y ,  
miRNA can be localized to specific organelles, such as stress 
granule or processing (P-) bodies, some of which are thought 
to  be  used  during  stress  (35).  At  the  same  time,  the  other 
strand, designated the passenger strand, is degraded (Fig. 1).
    Each mature miRNA interacts with a specific mRNA, typi-
cally through pairing of nucleotide bases between the miRNA 
sequence and complementary sequences in the mRNA 3’UTR. 
A s  g e n e  r e g u l a t o r s ,  t h e  f u n c t i o n s  o f  m i R N A  a r e  m e d i a t e d  
through  translational  repression  or  mRNA  degradation. 
Generally, whether target mRNAs are cleaved and degraded 
is  mainly  determined  by  the  complementarity  between 
miRNAs  and  target  mRNAs  (31,40,41,55).  miRNAs  are  be-
lieved  to  either  repress  mRNA  translation  or  reduce  mRNA 
stability following imperfect binding between the miRNA and 
the miRNA-recognition elements (MRE) within the 3’UTR of 
target genes (31,41,137). Interestingly, miRNAs display a sap-
tiotemporal pattern of expression and function and, therefore, 
are crucial in the regulation of various biological processes 
i n  v a r i o u s  s t a g e  ( 3 5 , 3 7 , 4 1 ) .
miRNAs IN THE INNATE IMMUNE RESPONSE
miRNAs play a key role in diverse biological processes, such 
as  embryogenesis,  differentiation,  inflammation,  viral  in-
fections, and carcinogenesis (58). The importance of miRNAs 
on immune system development and response has been re-
ported, as has the involvement of miRNAs in the regulation 
of immunity, including the development and differentiation of 
immune cells, antibody production, and inflammatory media-
tor release (137). The innate immune system is characterized 
by rapid response to pathogens and is mediated by macro-
p h a g e s ,  g r a n u l o c y t e s ,  D C s  a n d  n a t u r a l  k i l l e r  ( N K )  c e l l s  
(138,139). In contrast, the adaptive immune system, which is 
composed of T and B cells, is characterized by memory or 
secondary antigen-specific immune response. The NK T-cell 
system  bridges  innate  and  adaptive  immunity  (139).
    miRNA-mediated gene regulation is critical for normal cel-
lular functions, and as much as one-third of human mRNAs 
may be miRNA targets (140). Emerging evidence suggests that 
miRNAs play a key role in the regulation of immunological 
functions  including  innate  and  adaptive  immune  responses, 
development,  and  differentiation  of  immune  cells,  and  the 
prevention of autoimmunity (55-58,140) (Fig. 2). Mice defi-
cient  for  bic/miR-155  are  immunodeficient  and  bic/miR-155 
is required for the function of B-cells, T-cells, and DCs (59), 
indicating  that  bic/miR-155  plays  a  key  role  in  the  homeo-
stasis and function of the immune system. The evolutionarily 
conserved miR-155 has an important role in the mammalian MicroRNAs in Regulatory T Cells and Immune Response
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immune system, specifically in regulating T helper cell differ-
entiation and the germinal center reaction to produce an opti-
m a l  T - c e l l  d e p e n d e n t  a n t i b o d y  r e s p o n s e  ( 7 1 ) .  I n n a t e  i m -
munity  is  a  physiogenetically  ancient  biological  system  that 
multicellular  organisms  have  evolved  to  defend  themselves 
from  invading  pathogens.  The  job  of  recognition  of  the 
“nonself” from “self” in this system belongs to pattern recog-
nition receptors (PRRs). Acting as molecular sentinels, PRRs 
detect highly conserved microbial molecules (pathogen- asso-
ciated molecular patterns; PAMPS) and elicit pathogen-specif-
ic cellular responses that result in elimination of intruders as 
well as, in higher vertebrates, mobilization of the adaptive im-
mune system (61). There is evidence that miRNAs of the host 
may  impinge  on  the  viral  life  cycle,  viral  tropism,  and  the 
pathogenesis  of  viral  diseases  (64).  For  example,  human 
miR-32 has a direct negative effect on the replication of retro-
virus  primate  foamy  virus  type  1  (61,64).
    To elucidate the role of miRNA in the immune response 
in  vivo,  Moschos  et  al.  (141)  examined  the  different  ex-
pression of 104 miRNAs using real-time polymerase chain re-
action  (PCR)  during  the  innate  immune  response  in  the 
mouse  lung  following  exposure  to  aerosolized  lipopoly-
saccharide (LPS). Following challenge, rapid and transient in-
crease  in  both  the  mean  (4.3-fold)  and  individual  levels  of 
miRNA  expression  occurred  and  peaked  at  33  h.  Crucially, 
this  increase  was  correlated  with  a  reduction  in  the  ex-
pression  of  TNF-α,  keratinocye-derived  chemokine,  and 
macrophage  inflammatory  protein-2,  suggesting  a  potential 
role for miRNAs in the regulation of inflammatory cytokine 
production. Examination of the individual miRNA expression 
profiles revealed a time dependent increase in miR-21, -25, 
-27b, -100, -140, -142-3p, -181c, -187, -194, -214, -223, and 
-224  (141).
    Recent functional analysis of miRNAs in the immune system 
revealed that many cellular decisions are controlled by single 
miRNAs that entail significant down-regulation of one of few 
target  proteins  (71).  Investigation  of  miRNA/mRNA  pairs 
showed that miRNA-adjusted target protein levels are crucial 
at  specific  cellular  transition  points  (71). 
    While the role of miRNAs in cell fate decisions linked to 
proliferation  ,  differentiation,  and  apoptosis  has  long  been 
recognized, the importance of these noncoding small  RNAs 
on immune system development and response has only re-
cently become evident. In addition to facilitating cell fate de-
cisions of immune cells (e.g. miR-181a and miR-223), miRNAs 
also  regulate  central  elements  of  the  adaptive  immune  re-
sponse such as antigen presentation (e.g., miR155) and T-cell 
receptor  signaling  (e.g.,  miR-181a)  (63).  Furthermore,  the 
same study reported that miRNAs are involved in innate im-
munity through regulation of TLR signaling and cytokine re-
sponse (e.g., miR-146). Intriguingly, cellular miRNAs not only 
alter  immune  cell  development  and  function,  but  are  also 
able  to  directly  affect  viral  replication  (63).  Conversely,  vi-
rus-encoded  miRNAs  shape  the  host-virus  interactions  and 
regulate  the  viral  life  cycle  (63,64,142).
    In contrast to miR-146, which is mainly regulated by bacte-
rial  products,  miR-155  is  also  regulated  by  virally  relevant 
stimuli such as the synthetic TLR3 ligand poly(I:C) (64). In 
addition to TLR-mediated sensing of bacterial and viral patho-
gens,  miR-155  expression  is  also  strongly  induced  by  in-
flammatory cytokines such as antiviral cytokines IFN-β, IFN-
γ through TNF-α autocrine/paracrine signaling, suggesting 
that miR155 is a component of the innate immune response 
to  a  broad  range  of  inflammatory  mediators  (64).  As  dis-
cussed above, miR-155 is also essential for proper T-cell and 
B-cell response, as well as for interaction between DCs and 
T-cells. In contrast to miR-155, miR-146, and miR-137, another 
miRNA, miR-125b, is suppressed by LPS-treatment in a murine 
macrophage cell line (105). The function of miR-125b in mac-
rophages may be to ensure that the LPS pathway is turned 
off in the absence of microbial infection, while its down-regu-
lation in response to LPS may be needed for the macrophage 
inflammatory response (105). It seems clear that miRNAs are 
involved  in  the  regulation  of  innate  immune  response.
    Cytokine stimulation of immune cells also leads to a rapid 
shift  in miRNA  levels. For  example, miR-125b  and miR-155 
levels oscillate within 1 h of TNF stimulation in mouse Raw 
264.7 cells (105). These changes in miRNA levels enable the 
immune cells to limit the level and duration of immune re-
sponses to infections so that these responses do not become 
detrimental to the health of the organisms. Rapid changes in 
the levels of several miRNAs, however, were reported in the 
Huh7  hepatoma  cells  ltreated  with  IFN-β (63).
    Recent  studies  indicate  that  those  miRNAs  that  are  se-
lectively and/or highly expressed in immune cells, including 
the  miR-17-92  cluster,  miR-150,  miR-155,  miR-181,  and 
miR-223, have a ‘permissive’ function in the maturation, pro-
liferation, and differentiation of myeloid and lymphoid cells 
(65). Importantly, these actions of miRNAs often involve in-
teractions with transcription factors. In contrast, the rapid and 
transient induction of miR-9, miR-146a, and miR-155 may neg-
atively regulate the acute responses following activation of in-MicroRNAs in Regulatory T Cells and Immune Response
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nate immune response through the down-regulation of pro-
teins  involved  in  the  receptor-induced  signaling  pathway 
(65).
    Acute retroviral infection provokes rapid and striking innate 
i m m u n e  r e s p o n s e s  i n  w h a t  h a s  b e e n  t e r m e d  a  c y t o k i n e  
storm. These response are crucial in determining the course 
of disease, as a delicate balance must be achieved between 
pro-inflammatory  and  anti-inflammatory  processes.  The  for-
mer must be sufficiently ferocious to dampen viral replication 
and impede further infection, and the latter is needed to pre-
vent the tissue damage inherent in chronic activation of the 
immune system (64,67,143). Human immunodeficiency virus 
(HIV) and simian immunodeficiency virus (SIV) infection of 
macrophages induces IFN-β, with both proinflammatory and 
anti-inflammatory roles, which is the main type 1 IFN induced 
during the initial innate response to retroviral infections of the 
c e n t r a l  n e r v o u s  s y s t e m  ( C N S )  ( 6 7 ) .  I n t e r e s t i n g l y ,  W i t w e r  e t  
al.  recently  reported  that  miRNAs,  including  miR-26a,  -34a, 
-145, and let-7b, may directly regulate IFN-β in human and 
macaque  cells  (67).  In  primary  primate  macrophages,  the 
main cell type implicated in HIV and SIV infection in the CNS, 
specific  miRNAs  are  reduce,  whereas  miRNA  inhibitors  en-
hance, IFN-β protein production. These findings may have 
significant implications for the fine-tuning of innate immune 
response during retroviral infection and, potentially, for the 
therapeutic  modulation  of  innate  immune  responses  (67).
    Interestingly, Kosaka et al. profiled  miRNA expression in 
human breast milk and detected high expression levels of im-
mune related miRNAs in the first 6 months of lactation (62). 
Using a miRNA microarray, they detected 282 of 723 known 
human  miRNAs.  More  interestingly,  several  immune  related 
miRNAs were abundant in milk:  miR-155, a regulator of  T- 
and  B-cell  maturation  and  the  innate  immune  response; 
miR-181a and miR-181b, which are regulators of B-cell differ-
entiation and CD4＋ T-cell selection; the miR-17 and miR-92 
cluster, a ubiquitous regulator of B-cells, T-cells, and mono-
cyte development; miR-125b, a negative regulator of TNF-α 
production,  activation,  and  sensitivity;  miR-146b,  a  negative 
regulator  of  the  innate  immune  response;  miR-223,  a  regu-
lator of neutrophil proliferation and activation; and let-7i, a 
regulator of TLR4 expression in human cholangiocytes (62). 
I n  c o n t r a s t ,  T -  a n d  B - c e l l  r e g u l a t o r y  m i R - 1 5 0  w a s  n o t  
detected. In addition, it has been reported that other body 
fluid  and  serum  contain  sufficiently  stable  miRNA  signature 
(95,144-148).  Together,  these  findings  suggest  that  human 
breast milk contains miRNAs capable of transfer to immune 
cells to support the development of an infant’s immune sys-
tem and that human-to-human transfer of genetic material as 
miRNA  occurs  by  means  other  than  through  sexual  re-
production  (62,95).
miRNAs IN MACROPHAGES/MONOCYTES
LPS  stimulation  up-regulates  or  represses  the  expression  of 
miRNAs in macrophages. Among the LPS-responsive miRNAs 
characterized to date, miR-155 is up-regulated in response to 
LPS (105,149), promoting the expression of TNF-α and de-
stabilization of PU.1, a key mediator of monocyte and macro-
phage differentiation, and TLR4 transcription (150). miR-155 
a l s o  t a r g e t s  a n d  s u p p r e s s e s  S O C S 1  ( s u p p r e s s o r  o f  c y t o k i n e  
signaling 1), a critical regulator of STAT (Signal Transducer 
and Activator of Transcription) signaling in Treg cells (151) 
and  inositol  phosphatase  SHIP1  (35,55,149).  In  contrast, 
miR-125 inhibits the expression of TNF-α and is down-regu-
lated  in  LPS-treated  macrophages  (105).
    In the last decade, members of the Toll-like receptor (TLR) 
family have emerged as the primary evolutionarily conserved 
sensors of PAMP (64,152). Innate immune response to micro-
bial  infections  occurs  primarily  through  TLRs,  which  recog-
nize PAMP and elicit the biosynthesis of proinflammatory cy-
tokines  from  macrophages  and  other  cells  (152).  MAPK 
(mitogen-activated protein kinase) phosphatase (MKP-1) is an 
archetypical member of the dual-specificity phosphatase fam-
ily that deactivates MAPKs. Zhu et al. showed that MKP-1 is 
a direct target of miR-101 (a tumor-related miRNA) and that 
expression of miR-101 is induced by multiple TLR ligands, in-
cluding  LPS  or  peptidoglycan  (152).  Moreover,  they  also 
showed that treatment of cells with dexamethasone, a widely 
used anti-inflammatory agent, markedly inhibits miR-101 ex-
pression and enhances the expression of MKP-1 in LPS-stimu-
lated  macrophages.  Together,  these  data  indicate  that  miR- 
101 regulates the innate immune responses of macrophages 
to  LPS  through  the  targeting  of  MKP-1.
    To  examine  the  potential  involvement  of  miRNAs  in  the 
regulation of the innate immune response, Taganov et al. an-
alyzed the expression of 200 miRNAs after exposure of THP-1 
cells to LPS. They found that production of mature forms for 
several  of  them  (miR-146a/b,  miR-132,  and  miR-155)  is  in-
duced and that analysis of miR-146a and miR-146b gene ex-
pression revealed a pattern of induction in response to a vari-
ety of microbial components and proinflammatory cytokines 
(153). Additionally, they determined that TNF receptor-asso-MicroRNAs in Regulatory T Cells and Immune Response
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ciated factor 6 (TRAF-6) and IL-1 receptor associated kinase 
( I R A K )  r e p r e s e n t  p o t e n t i a l  m o l e c u l a r  t a r g e t s  o f  m i R - 1 4 6  
through  an  experiment  with  3’  UTR  luciferase  reporters. 
These findings suggest that miR-146a may function as a novel 
negative  regulator  that  helps  to  fine-tune  the  immune  re-
sponse  (153).
    MiR-155 is one of the first miRNAs linked with cancer. To 
test whether virally relevant stimuli induce expression of spe-
cific miRNAs, O’Connell et al. used microarray technology to 
identify miRNAs induced in primary murine macrophages af-
ter  exposure  to  polyriboinosinic:polyribocytidylic  acid 
[poly(I:C)] or IFN-β (149). It was found that miR-155 was 
the  only  miRNA  of  those  tested  that  was  substantially 
up-regulated  by  both  stimuli.  Further  investigation  revealed 
that  several  TLR  ligands  increased  miR-155  expression 
through  either  MyD88  (myeloid  differentiation  factor  88)  or 
TRIF (TLR domain -containing adaptor-inducing IFN-β) sig-
naling, whereas IFNs required TNF-α autocrine signaling to 
up-regulate  miR-155.  Inhibition  of  c-Jun  N-terminal  kinase 
(JNK)  blocked  both p o l y ( I : C )  a n d  T N F - α  induction  of 
miR-155,  indicating  a  role  for  MAPK  signaling  in  the  regu-
lation of miR-155 levels (149). Together, because miR-155 is 
known to be function as  an oncogene,  these results reveal 
miR-155 as a component of the inflammatory response and 
suggest that this oncogenic miRNA may prove to be a link 
between  inflammation  and  cancer.  Tili  et  al.  reported  that 
miR-155 and miR-125b play important roles in the innate im-
mune response (105). They also found that LPS stimulation 
o f  m o u s e  m a c r o p h a g e s  r e s u l t e d  i n  t h e  u p - r e g u l a t i o n  o f  
miR-155 and down-regulation of miR-125 levels. Furthermore, 
levels of miR-155 and miR-125b in macrophages displayed os-
cillatory changes in response to TNF-α. They also showed 
that miR-155 most probably directly targets transcript coding 
for  several  proteins  involved  in  LPS  signaling,  such  as  the 
Fas-associated death domain protein (FADD), IκB kinase ε 
(IKKε), and the TNF receptor (TNFR superfamily)-interacting 
serine-threonine  kinase  1  (Ripk1),  while  enhancing  TNF-α 
translocation. Additionally, they found that Eμ-miR-155 trans-
genic mice produced higher levels of TNF-α when exposed 
t o  L P S  a n d  w e r e  h y p e r s e n s i t i ve  to  LPS/D-galactosamine-in-
duced septic shock (105). These results may suggest the pos-
itive role of miR-155 in the regulation of the release of in-
flammatory  mediators  during  the  innate  immune  response. 
Interestingly,  in miR-155 knock-out mice,  miR-155 was  also 
verified as a requirement for normal immune function (59). 
Rodriguez et al. have shown that bic/miR-155 regulates the 
function  of  T-  and  B-lymphocytes  and  DCs,  leading  to  an 
overall diminution of immune responses (59). Identification 
o f  m u l t i p l e  n o v e l  p o t e n t i a l  t a r g e t s  o f  m i R - 1 5 5  s u p p o r t s  t h e  
view that bic/miR-155 is a core regulator of gene expression 
in multiple cell types, with a “targetome” optimized to modu-
late the immune response (59). Moschos et al. investigated 
miRNA  expression  in  mouse  lungs  after  LPS  exposure  and 
found  a  rapid  and  transient  increase  in  the  expression  of 
miRNAs. Particularly, 12 miRNAs (miR-21, miR-25, miR-27b, 
miR-100,  miR-140,  miR-1423p,  miR-18c,  miR-187,  miR-194, 
miR-214, and miR- 223) were regulated in a time-dependent 
manner  (141).  Of  note,  miR-146  and  miR-155  were  not 
up-regulated, in contrast to results obtained in macrophages. 
Interestingly,  the  lack  of  effect  of  dexamehasone  in  either 
control or challenged animals implies that the actions of glu-
corcorticoids  per  se  are  not  mediated  through  changes  in 
miRNA expression and that LPS-induced increases in miRNA 
expression are not mediated via classical inflammatory tran-
scription  factors.
    Interestingly, Sonkoly et al. recently found miR-146 to be 
associated with psoriasis, a chronic inflammatory skin disease, 
indicating that alteration in the fine-tuning of the innate im-
mune response by miRNAs may contribute to inflammatory 
disorders (64). Effective recognition of viral infection and sub-
sequent triggering of antiviral innate and adaptive immune re-
sponse are essential for the survival of the host. Upon recog-
nition of viral components, host cells are activated to produce 
type I IFN and pro-inflammatory cytokines (64). Viruses are 
recognized  by  PRRs,  including  TLRs  and  retinoic  acid-in-
ducible gene 1 (RIG-1)-like helicase (RLH). RIG-1 was identi-
fied as a cytoplasmic viral RNA detector (149). Hou et al. ana-
lyzed the expression profile of miRNAs in mouse peritoneal 
macrophages during vesicular stomatitis virus (VSV) infection 
(154). They found that several miRNAs, including miR-146a, 
miR-155,  miR-7a,  miR-574-5p,  and  miR-125a-5p  were  sig-
nificantly up-regulated and that VSV infection could up-regu-
late miR-146a expression in macrophages through a MyD88- 
independent,  but  RIG-1-NF-κB-dependent,  manner.  Impor-
tantly, they also demonstrated that miR-146a negatively-regu-
lated VSV infection-triggered type I IFN production in a feed-
b a c k  r e a c t i o n  b y  i m p a i r i n g  t h e  R I G - 1  p a t h w a y  t h r o u g h  t h e 
targeting of TRAF6, IRAK1, and IRAK2. Furthermore, they dis-
cerned associations of IRAK1 and IRAK2 with FADD (Fas-as-
sociated death domain), an important adaptor in RIG-1 signal-
ing, in a VSV infection-inducible manner. The collective data 
from  their  study  demonstrated  that  miR-146a  is  a  feedback MicroRNAs in Regulatory T Cells and Immune Response
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negative regulator of the RIG-1 signaling and RIG-1-depend-
ent  anti-viral  pathways  (154).
  A c t i v a t i o n  o f  m a c r o p h a g e s  b y  L P S  i n i t i a t e s  f e e d b a c k  i n -
hibitory loops that aim to establish tolerance to a subsequent 
LPS stimulus. Negative feedback signals either inhibit the ex-
pression of genes that are required for the response to LPS, 
such  as  the  LPS  receptor  TLR4,  or  promote  the  expression 
of  genes  that  inhibit  the  response,  such  as  SOCS1  and 
IRAK-M. Negative regulators of TLR signaling such as SOCS1 
and IRAK-M are up-regulated within 2 h from the start of the 
stimulation (105,151,153). Akt (also known as PKB) is a fam-
ily  of serine-threonine  protein kinases  that  are  activated  by 
PI-3K  (phosphoinositide-3  kinase)  and  that  play  key  regu-
latory roles in a host of cellular functions including cell sur-
vival, cell proliferation, differentiation, and intermediary me-
tabolism (155). Stimulation of macrophages with the TLR4 ag-
onist LPS activates PI-3K and its downstream targets, includ-
ing  Akt  kinase.  Thus,  activation  of  the  PI-3K-Akt  pathway 
suppresses  LPS-activated  MAPK  and  NF-κB  signaling  cas-
c a d e s  i n  m o n o c y t e s  a n d  D C s ,  r e s u l t i n g  i n  d e c r e a s e d  p r o -
duction  of  TNF-α and  other  cytokines  (155).  Interestingly, 
Androulidaki et al. investigated the role of Akt1 in the regu-
lation  of  miRNA  expression  in  LPS-stimulated  macrophages 
(155).  They  found  that  LPS-treated  Akt
−/−  macrophages 
failed to induce miRNA let-7e and expressed higher amounts 
of miR-155, in contrast to Akt
＋/＋ macrophages. In silico anal-
ysis  and  transfection  studies  revealed  that  let-7e  controlled 
TLR4 and miR-155 repressed SOCS1, and that these miRNAs 
were under the control of Akt1. As a result, Akt
−/− macro-
phages were hyper-responsive to LPS and failed to develop 
endotoxin tolerance in culture and in vivo. In addition, they 
showed that introduction of these miRNAs in Akt1
−/− macro-
phages restored their response to LPS (155). These results in-
dicate that Akt1 controls macrophage responsiveness to LPS 
endotoxin tolerance by regulating the expression of miRNAs.
miRNAs IN GRANULOCYTES
Hematopoiesis is a life-long, highly-regulated multistage proc-
ess wherein a pluripotent self-renewing hematopoietic stem 
cell (HSC) gives rise to all blood cell lineages. A recent study 
showed that hematopoietic lineage differentiation, the process 
of continuous development of HSCs into at least eight differ-
ent  blood  lineage,  is  controlled  by  miRNAs  (38).  As  men-
tioned earlier, three miRNAs that are preferentially expressed 
in  murine  hematopoietic  tissues  have  been  discovered: 
miR-181, miR-142, and miR-223 (38). miR-181 is very strongly 
expressed  in  the  thymus,  brain,  and  lung,  and  miR-223  is 
nearly  exclusively  expressed  in  bone  marrow,  whereas 
miR-142  is  expressed  in  all  hematopoietic  tissues  (38). 
Interestingly,  the  ectopic  expression  of  miR-181  in  mouse 
hematopoietic precursor cells leads to an increased fraction 
o f  B  l i n e a g e  c e l l s  ( 3 8 ) .
    Fazi et al. showed that human granulocytic differentiation 
is controlled by a regulatory circuitry involving miR-223 and 
two  transcriptional  factors,  NF-1A  (nuclear  factor-1A)  and 
C/EBPα (the CCAAT enhancer proteins). These two factors 
compete for binding to the miR-223 promoter. NF-1A main-
tains  miR-223  at  low  levels,  whereas  its  replacement  by 
C/EBPα, following retinoic acid (RA)-induced differetiation, 
up-regulates  miR223  expression  (156).  The  data  from  the 
study indicated that miR-223 plays a crucial role during gran-
ulopoiesis and point to NF1-A repression as an important mo-
lecular pathway mediating gene re-programming in this cell 
lineage  (156).
    Neutrophils are an essential part of the innate immune re-
sponse as they are critical for the first line of defense against 
bacteria  and  fungi.  Using  a  loss-of-function  allele  in  mice, 
Johnnidis  et  al.  reported  that  the  myeloid-specific  miR-223 
negatively regulates progenitor proliferation and granulocyte 
differentiation and activation, and that miR-223 mutant mice 
have an expanded granulocytic compartment resulting from 
a cell-autonomous increase in the number of granulocyte pro-
g e n i t o r s  ( 1 5 7 ) .  T h e y  a l s o  d e m o n s t r a t e d  t h a t  M e f  ( m y e l o i d  
ELF-1-like factor) 2c, a transcription factor that promotes mye-
loid progenitor proliferation, is a target of miR-223, and that 
genetic  ablation  of  Mef2c  suppresses  progenitor  expansion 
and corrects the neutrophilic phenotype in miR-223 null mice. 
Additionally, granulocytes lacking miR-223 are hypermature, 
hypersensitive to activating stimuli, and display increased fun-
gicidal activity (157). As a consequence of this neutrophil hy-
peractivity, miR-223 mutant mice spontaneously develop in-
flammatory lung pathology and exhibit exaggerated tissue de-
struction after endotoxin challenge (157). The latter results in-
dicate  that  miR-223  is  an  intrinsic  modulator  of  neutrophil 
sensitivity,  similar  to  the  role  proposed  for  miR-181,  which 
acts as a ‘rheostat’ controlling T-cell activation (158). Surpris-
ingly,  brief  exercise  alters  the m i R N A  p r o f i l e  i n  c i r c u l a t i n g  
neutrophils  in  humans  (46).MicroRNAs in Regulatory T Cells and Immune Response
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miRNAs IN NK CELLS
NK  cells  were  named  after  their  ability  to  mediate  sponta-
neous  cytotoxicity  during  the  innate  immune  response. 
However, it has become clear that they play an equally im-
portant role in restricting infection and assisting in the devel-
opment of adaptive immune responses via their ability to pro-
duce  cytokines  (159,160).
  NK cells are a key components of the innate immune sys-
tem, providing early cellular defense against virus and intra-
cellular pathogens, and contribute to the early detection and 
d e s t r u c t i o n  o f  t r a n s f o r m e d  c e l l s  ( 6 4 ) .  V e r y  r e c e n t l y ,  u s i n g  
mice with conditional deletion of Dicer and DiGerorge syn-
drome critical region 8 (Dger8), Bezman et al. developed a 
system for deletion of either Dicer or Dger8 in peripheral NK 
cells (161). They found that Dicer- and Dger8-deficient NK 
cells were significantly impaired in survival and turnover, and 
had impaired function of the immunoreceptor tyrosine-based 
activation  motif  (ITAM)-containing  activating  NK  cell  re-
ceptors.  They  further  demonstrated  that  both  Dicer  and 
Dger8-dependent  pathways  were  indispensable  for  the  ex-
pansion of Ly49H＋NK cells during mouse cytomegalovirus 
infection. Thus, their data indicate a critical role for miRNAs 
in controlling NK cell homeostasis and effector function, with 
implication for miRNA regulation of diverse aspects of NK cell 
biology (161). One notable example of an immune activating 
receptor critically involved in tumor and virus elimination is 
NKG2D (160). This dominant killer receptor is expressed by 
NK cells and T-cells, and recognizes stress molecules that are 
up-regulated  on  transformed,  virus-infected,  and  other  dis-
eased  or  stressed  cells.  MICA  and  MICB  are  among  the 
stress-induced NKG2D ligands (160). Several stress pathways 
lead to the up-regulation of NKG2D. However, very little is 
known  concerning  the  regulation  of  NKG2D  ligand  ex-
pression in normal conditions. Stern-Ginossar et al. reported 
a  group  of  endogenous  cellular  miRNAs  that  control  MICA 
and MICB expression by binding to MICA and MICB 3’UTR 
sites (160). Notably, many of the identified cellular miRNAs 
a r e  o v e r - e x p r e s s e d  i n  v a r i o u s  t u m o r s .  T h e  a u t h o r s  d e m o n -
strated  that  these  miRNAs  enable  tumors  to  avoid  immune 
recognition, prompting the proposal of a model in which cel-
lular miRNAs prevent self recognition and promote ‘tumor es-
cape’  (160).
miRNAs IN NK T-CELLS
NK T-cell (NKT) biology has emerged as a new field of re-
search at the frontier between innate and adaptive immunity 
(139). Conditional deletion of Dicer has provided insight into 
the role of miRNAs in controlling the development of B-cells, 
T-cells, and DCs (84-87,162-165). In one study, dicer deletion 
early  in  T-cell  development  (DN,  double  negative  stage) 
caused a 10-fold decrease in double positive (DP) and sin-
gle-positive (SP) thymocyte numbers, although the CD4/CD8 
lineage choice was unaffected (163). Dicer deletion at a later 
stage of T-cell development (DP stage) did not alter the num-
ber and composition of mainstream thymocytes, although it 
resulted  in  a  substantial  reduction  in  thymic  CD4＋CD25＋
Foxp3＋nTreg cells (84,87). In the peripheral compartment, 
the mice showed a modest reduction in CD4＋ and CD8＋ 
T cells, Th1 polarization, and increased apoptosis of CD4＋ 
T  cells  (164).  Foxp3-driven  deletion  of  Dicer  selectively  in 
Treg cells impairs peripheral homeostasis (85) and suppressor 
functions (85,86). Recently, Fedeli et al. investigated the in-
variant  NKT  (iNKT)  cell  development  in  a  set  of  mice  in 
which  Dicer  was  deleted  from  cortical  thymocytes  (165). 
Interestingly, they found that Dicer deletion resulted in a sub-
stantial reduction of iNKT cells in the thymus and their dis-
appearance  from  the  periphery,  unlike  mainstream  T-cells. 
They also found that, without Dicer, iNKT cells were unable 
to complete their innate effector differentiation and displayed 
a defective homeostasis due to increased cell death (165). In 
this study, differentiation and homeostasis of iNKT cells re-
quired Dicer in a cell-autonomous fashion. Furthermore, they 
identified a miRNA profile specific for iNKT cells (165). These 
data define a critical role of the Dicer-dependent miRNA path-
way  in  the  physiology  of  iNKT  cells.
miRNAs IN DCs
DCs  are  immune  cells  that  effectively  link  the  innate  and 
a da pt iv e ar ms  o f t he  im mu n e system.  They  are  considered 
a professional antigen-presenting cell population because of 
their  unique  capacity  to  induce  the  activation  and  differ-
entiation of naive T-cells at the crossroads of innate and adap-
tive immunity (69,166). Included in this function is the ability 
to initiate immunogenic as well as tolerogenic responses from 
T-cells,  a  fundamental  step  in  regulating  homeostasis. 
Numerous  subpopulations  of  DCs  have  been  identified  to 
date, including interstitial DCs, dermal DCs, Langerhans cells, MicroRNAs in Regulatory T Cells and Immune Response
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plasmacytoid DCs, and inflammatory DCs (166). Importantly, 
there is accumulating evidence that interactions between DC 
and Treg cells play a crucial role in the balance between im-
mune response and tolerance (111). Moreover, several lines 
of experimental evidence suggest that different subset of the 
functional status of DC are also involved in the prognosis of 
Treg cell differentiation (111,166). Although relatively little is 
known about miRNA in DCs, Ceppi et al. recently reported 
that, in response to LPS, several miRNAs are regulated in hu-
man  monocyte-derived  DCs  (1 6 7 ) .  A m o n g  t h e s e  m i R N A s ,  
miR-155 is highly up-regulated during maturation. They also 
identified the TLR/IL-1 inflammatory pathway as a general tar-
get of miR-155. Furthermore, they demonstrated that miR-155 
directly controls the level of TAB2, an important signal trans-
duction molecule (167). Their observations suggest that in hu-
man mature DCs, miR-155 is part of a negative feedback loop 
that down-modulates inflammatory cytokine production in re-
sponse to microbial stimuli (167). More recently, Holmstrom 
e t  a l .  i n v e s t i g a t e d  t h e  d i f f e r e n t i a l  e x p r e s s i o n  o f  m i R N A s  i n  
m a t u r e  D C s  ( 1 6 8 ) .  U s i n g  m i c r o a r r a y - b a s e d  s c r e e n i n g ,  t h e y  
found  that  12  miRNAs  were  differentially  expressed  in  two 
D C  p h e n o t y p e s .  O f  t h e s e ,  f o u r  m i R N A s  ( h s a - m i R - 1 5 5 ,  
hsa-miR-146a, hsa-miR-125a-6p, and hsa-miR-29a) were vali-
dated  by  real-time  PCR  and  Northern  blotting  (168).
    DCs play important roles in linking the innate and adaptive 
immune  responses.  However,  few  miRNAs  regulate  the  in-
nate response and antigen presenting capacity (APC) function 
of DCs (69). Calcium/calmodulin-dependent protein kinase II 
(CaMKII), a major downstream effector of calcium (Ca
2＋), is 
an important regulator of the maturation and function of DCs. 
Liu et al. examined whether miRNA can regulate the innate 
response  and  APC  function  of  DCs  by  targeting  CaMKIIα 
(69). They found that three members of the miRNA-148 fam-
ily (miR-148a, miR-148b, and miR-152) are negative regulators 
of the innate response and APC of DCs. They also found that 
miR-148/152 expression was up-regulated, whereas CAMKII-
alpha expression was down-regulated in DCs on maturation 
and  activation  induced  by  TLR  agonists.  Additionally,  they 
demonstrated  that  miR148/152  in  turn  inhibited  the  pro-
duction of cytokines including IL-6, IL-12, TNF-α, and IFN-
β up-regulation  of  major  histocompatibility  (MHC)  class  II 
expression  and  DC-initiated  antigen-specific  T-cell  pro-
liferation by targeting CAMKIIalpha (69). These findings sug-
gest that miRNA-148/152 may act as a fine-tuner in regulating 
the  innate  immune  response  and  APC  of  DCs.
miRNAs IN THE ADAPTIVE IMMUNE RESPONSE
miRNAs are emerging as key regulators of the development 
and function of adaptive immunity. The contribution of spe-
cific miRNAs to the adaptive immune response becomes even 
more  apparent  during  the  effector  phases:  class  -switching 
and germinal center formation in B-cells, differentiation into 
functional lineages in T-cells, and activation of antigen-pre-
senting  cells  through  pattern-recognition  pathways  (169). 
With the capacity of miRNA to alter the survival and death 
of T- and B-cells, control over miRNA expression is essential 
t o  p r e v e n t  a d a p t i v e  i m m u n e  c e l l s  f r o m  u p - r e g u l a t e d  p r o l i -
feration. miRNA can act both as ‘oncomirs’ and tumor sup-
pressors,  thus  dysregulaltion  of  miRNA  in  lymphocytes  can 
cause malignancies (66,169). Both developmental and func-
t i o n a l  r o l e s  o f  m i R N A  a r e  r a p i d l y  b e i n g  d i s c o v e r e d .  T h e s e  
studies are either focused on the network-wide role of miRNA 
or  the  functions  of  specific  miRNA.  The  advantage  of  net-
work-wide studies is the ability to knockout the entire miRNA 
regulatory network, typically by Cre-Lox mediated excision of 
genes  involved  in  biogenesis,  such  as  Dicer,  Drosha,  or 
Argonaute  (84-87).  This  allows a  c e l l  t y p e  t o  b e  r a p i d l y  
s c r e e n e d  f o r  m i R N A - d e p e n d e n t  p r o c e s s e s  i n  a n  u n b i a s e d  
fashion,  as  every  miRNA-dependent  process  should  be 
disrupted. The alternative strategy is to focus on the function 
of  single  miRNA,  by  knockout  or  overexpression,  and  de-
termine the  affected  phenotypes. This  strategy  is  successful 
at detecting more subtle miRNA functions, in conjunction with 
mechanistic  information  (143,151,161,169).
miRNAs IN B-CELLS
B-cell development and differentiation in mice and humans 
are complex processes that begin in fetal liver and bone mar-
row with the proliferative expansion of progenitor cells that 
undergo sequential rearrangements of their antigen receptor 
repertoire (38). The role of miRNA in B-cell development and 
B-cell lymphomagenesis is largely unknown (170). One of the 
key  roles  of  miRNA  in  B-cells  is  to  allow  efficient  differ-
entiation  in  the  bone  marrow.  Removal  of  the  miRNA  net-
work through deficiency in Dicer or Ago2 results in a sub-
stantial  defect  in  B-cell  differentiation  from  the  pre-B-cell 
stage (162). Chen et al. identified three miRNAs that are spe-
cifically  expressed  in  hematopoietic  cells  and  showed  that 
their expression is dynamically regulated during early hema-
topoiesis and lineage commitment (38). One of these miRNA, MicroRNAs in Regulatory T Cells and Immune Response
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miR-181, is preferentially expressed in the B-lymphoid cells 
o f  m o u s e  b o n e  m a r r o w .  I t s  e c t o p i c  e x p r e s s i o n  i n  h e m a -
topoietic  stem/progenitor  cells  leads  to  an  increase  fraction 
of B-lineage cells in both tissue-culture differentiation assay 
and adult mice (38). Eis et al. showed that clinical isolates 
of several types of B-cell lymphomas, including diffuse large 
B-cell  lymphoma  (DLBCL),  have  10-to  30-fold  higher  copy 
numbers  of  miR-155  than  do  normal  circulating  B  cells. 
Similarly, the quantities of bic (B-cell integration cluster) RNA 
are elevated in lymphoma cells (171). Significantly higher lev-
els of miR-155 are present in DLBCLs with an activated B-cell 
phenotype.  Because  patients  with  activated  B-cell-type 
DLBCL have a poorer clinical prognosis, quantification of this 
miRNA may be diagnostically useful (171). Evidence suggest-
ing that bic is a primary miRNA transcript containing the ma-
t u r e  m i R - 1 5 5  a s  p a r t  o f  a  R N A  h a i r p i n  i s  a c c u m u l a t i n g .  
Kluiver et al. demonstrated that expression of primary miRNA 
bic and its derivative miR-155 in Hodgkin’s lymphomas, pri-
mary  mediasinal  B-cell  lymphoma  and  DLBCL  (172). 
However, expression of bic and mi R- 15 5  is  n ot  a  c om m on 
finding in Burkitt lymphoma (173). Mice that are bic-deficient 
are  immunodeficient  and  fail  to  generate  high  levels  of 
class-switched antibody upon immunization with thymus-de-
pendent and thymus-independent antigens (174). In addition, 
bic-deficient T-cells show skewed differentiation into the Th2 
lineage  under  a  variety  of  in  vitro  culture  conditions. 
Microarray analysis of bic-deficient B- and T-cells under dif-
ferent  conditions  has  revealed  a  wide  spectrum  of  targets 
regulated by an miR-155 and has suggested mechanisms for 
the  regulation  of  lymphocyte  differentiation  by  a  single 
miRNA (174). Expression of bic and miR-155 in three latency 
type  III  EBV  (Epstein-Barr  virus)-positive Burkitt  lymphoma 
cell lines and in all primary posttranplantation lymphoprolifer-
ative disorder cases suggests a possible role for EBV latency 
type III specific proteins in the induction of bic expression 
(175). 
  As mentioned, recent studies have suggested the involve-
ment  of  miRNA  in  the  initiation  and  progression  of  cancer 
and  miR-155,  and  bic,  its  host  gene,  has  been  reported  to 
accumulate in human B-cell lymphomas (171-173). These re-
ports provide indirect evidence that miR-155 may play a role 
in B-cell development and lymphomagenesis. The most direct 
evidence so far for the ability of miRNAs influencing immune 
responses has come from animal models with both ectopic 
expression and knockout of candidate miRNA. Costinean et 
al. reported that the transgenic mice carrying a miR-155 trans-
gene  whose  expression  is  targeted  to  B-cells  (Eu-mmu- 
miR-155) exhibit initially preleukemic pre-B-cell proliferation, 
evident in spleen and bone marrow, and later develop frank 
B-cell malignancy (175). miR-155 is expressed by cells of the 
immune  system  after  activation  and  has  been  shown  to  be 
required  for  antibody  production  after  vaccination  with 
Samonella (150). Vigorito et al. showed that B-cells lacking 
miR-155 generate reduced extrafollicular and germinal center 
responses and fail to produce high-affinity IgG1 antibodies, 
and  that  the  transcription  factor  Pu.1  is  a  direct  target  of 
miR-155-mediated inhibition (150). Rodriguez et al. demon-
strated  a  requirement  of  bic/miRNA-155  for  the  function  of 
B-cells  (59).  Using  genetic  deletion  and  transgenic  appro-
aches, Thai et al. showed that the evolutionarily conserved 
miRNA-155 has an important role in the mammalian immune 
system, specifically in regulating T helper cell differentiation 
and  the  germinal  center  reaction  to  produce  an  optimal 
T-cell-dependent antibody response. miR-155 exerts this con-
trol, at least in part, by regulating cytokine production (176). 
These results also suggest that individual miRNAs can exert 
critical  control  over  mammalian  differentiation  processes  in 
vivo  (176).
    It has become clear over the past few decades that the vari-
ous  phases  of  B-cell  development  and  response  are  under 
distinct  programs  of  transcriptional  control,  which  are  acti-
vated  in  the  cells  by  environmental  cues.  miR-150  controls 
transcription factor c-Myb expression in vivo and dramatically 
affects  B-cell  development  (177).
    miR-150  is  mainly  expressed  in  the  lymph  nodes  and 
spleen, and is highly up-regulated during the development of 
mature  T-  and  B-cells  (178).  In  this  study,  expression  of 
m i R - 1 5 0  w a s  s h a r p l y  u p - r e g u l a t e d  a t  t h e  i m m a t u r e  B - c e l l  
stage. Over-expression of miR-150 in hematopoietic stem cells 
had little effect on the formation of T-cells, but the formation 
o f  m a t u r e  B - c e l l s  w a s  g r e a t l y  i m p a i r e d .  F u r t h e r m o r e ,  p r e -
mature expression of miR-150 blocked the transition from the 
pro-B  to  the  pre-B  stage  (178).
    To  explore  the  role  of  Dicer-dependent  control  mecha-
nisms in B lymphocyte development, Koralov et al. ablated 
this enzyme in early B cell progenitor (162). This resulted in 
a  developmental  block  at  the  pro-  to  pre-B-cell  transition. 
Gene-expression  profiling  revealed  a  miR17-92  signature  in 
the  3’UTRs  of  genes  upregulated  in  Dicer-deficient  pro-B- 
cells.
    To examine the physiologic effects of an individual miRNA- 
mRNA  interaction  in  vivo,  Dorsett  et  al.  generated  Aicda
155 MicroRNAs in Regulatory T Cells and Immune Response
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mice  that  harbored  a  mutation  in  the  putative  miRNA-155 
binding site in the 3’UTR of activation-induced cytidine deam-
inase  (AID).  AID  is  required  for  immunoglobulin  gene  di-
versification  in  B  lymphocytes  (179).  They  also  found  that 
miR-155 can act as a tumor suppressor by reducing poten-
tially  oncogenic  translocations  generated  by  AID.
    To understand the role of miRNAs in B cell function and 
lymphomagenesis,  very  recently,  Basso  et  al.  generated 
s h o r t - R N A  l i b r a r i e s  f r o m  n o r m a l  h u m a n  B  c e l l s  a t  d i f f e r e n t  
stages of development (naive, germinal center, and memory) 
and from a Burkitt lymphoma cell line (170). Using a combi-
nation of cloning and computational analysis, they identified 
178  miRNAs  (miRNome)  expressed  in  normal  and/or  trans-
formed B-cell libraries. Most notably, the B cell miRNome in-
cluded new 75 miRNAs. Numerous miRNA were expressed 
in a stage- or transformation-specific fashion in B-cells, sug-
gesting specific functional or pathologic roles (170). These re-
sults may provide a resource for studying the role of miRNAs 
in  B-cell  development,  immune  function,  and  lymphoma-
g e n e s i s .  T h r o u g h  c o n c o m i t a n t  m i R N A  a n d  m R N A  p r o f i l i n g ,  
Zhang  et  al.  demonstrated  a  potential  regulatory  role  for 
miRNAs  at  every  stage  of  the  mature  B-cell  differentiation 
process  (180).  In  addition,  they  experimentally  identified  a 
direct role for the miRNA regulation of key transcription fac-
tors  in  B-cell  differentiation:  LMO2  and  PRDM  1(Blimp  1). 
They  also  profiled  the  miRNA  of  B-cell  tumors  and  found 
that, in contrast to many other malignancies, common B-cell 
malignancies do not down-regulate miRNA expression (180). 
Expression of lineage-specific miRNA could correctly predict 
the lineage of B-cell malignancies in more than 95% of the 
cases. Thus, their data demonstrate that miRNAs may be im-
portant in maintaining the mature B-cell phenotype in normal 
and  malignant  B  cells  (180).
    Belver et al. have examined role of miroRNAs in terminal 
B-cell differentiation by analyzing Cd19-Cre
ki/＋Dicer1f
l/fl mice 
(92). In the absence of Dicer, the transitional and marginal 
zone B-cell compartments were overrepresented and follicular 
B-cell generation was impaired. Interestingly, microRNA anal-
ysis revealed that miR-185, a microRNA overexpressed in fol-
licular  cells,  dampened  B-cell  receptor  (BCR)  signaling 
through  Bruton  tyrosine  kinase  down-regulation.  They  also 
found that Dicer-deficient B-cells had a skewed BCR reper-
toire with hallmarks of autoreactivity, which correlated with 
high  titers  of  autoreactive  antibodies  in  serum  and  auto-
immune features in females (92). Interestingly, miRNAs pre-
vented the generation of autoimmunity and, importantly, the 
autoimmune diseases observed in Dicer-deficient animals pre-
dominanted in female rather than male mice, very much re-
sembling the profound prevalence of female incidence in var-
ious autoimmune disease in humans (13,68). Therefore, the 
analysis  of  miRNA  expression  profiles  can  prove  clinically 
useful in the diagnosis and prognosis of autoimmune disease.
miRNAs IN CONVENTIONAL T-CELLS
Two studies showed an important role for the miRNA path-
way in the development of mature T cells (163,164). In one, 
Cobb et al. demonstrated that deletion of Dicer at an early 
stage of T-cell development compromised the survival of αβ 
lineage cells, whereas the number of γδ-expressing thymo-
cytes  were  not  affected  (163).  Most  remarkably,  given  that 
one third of mammalian mRNA target, Dicer seems to be dis-
pensable for CD4/CD8 lineage commitment. Thus, although 
Dicer seems to be critical for the development of the early 
embryo, it may have limited impact on the implementation 
of some lineage-specific gene expression programs (163). In 
the second study, Muljo et al. generated a conditional allele 
of dicer-1 in the mouse (164). They reported that specific de-
letion  of  dicer-1  in  the  T-cell  lineage  resulted  in  impaired 
T-cell development and aberrant T helper cell differentiation 
and cytokine production. A severe block in peripheral CD8＋ 
T-cell development was observed upon dicer-1 deletion in the 
thymus. However, Dicer-deficient CD4＋ T-cells, although re-
duced in numbers, were viable. These cells were defective 
in miRNA processing, and upon stimulation they proliferated 
poorly and underwent increased apoptosis (164). Dicer dele-
tion early in T-cell development induced by a Cre transgene 
driven by the lck promotor, lckCre, expressed from the dou-
ble-negative (DN) 2 stage onward, resulted in a sharp reduc-
tion  of  miRNAs  by  the  double-positive  (DP)  stage  and  a 
10-fold drop in the number of TCR-αβ thymocytes (18,163). 
Treg  cells  have  a  miRNA  profile  distinct  from  conventional 
CD4 T-cells (87). A partial Treg cell-like miRNA profile is con-
ferred by the enforced expression of Foxp3 and, surprisingly, 
by  the  activation  of  conventional  CD4  T-cells  (87).
    Although hundreds of miRNAs are present in the mamma-
lian  genome,  genetic  studies  addressing  their  physiological 
roles  are  at  an  early  stage.  miR-155  is  encoded  within  an 
exon of the non-coding RNA known as bic, and high levels 
of  bic  expression  are  induced  upon  antigen  receptor  stim-
ulation of B- and T-cells, as well as TLR stimulation of macro-
phage and DCs (174). Rodriguez et al. reported that mice de-MicroRNAs in Regulatory T Cells and Immune Response
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ficient for bic/miRNA-155 are immunodeficient and display in-
creased  lung  airway  remodeling  (59).  The  authors  demon-
strated  a  requirement  of  bic/miRNA-155  for  the  function  of 
B-cells,  T-cells,  and  DCs.  Transcription  analysis  of  bic/ 
miRNA-155-deficient CD4＋ cells identified a wide spectrum 
of  miRNA-155-regulated  genes,  including  cytokines,  chemo-
kines, and transcription factors. The study results suggest that 
bic/microRNA-155  play  a  key  role  in  the  homeostasis  and 
function of the immune system (59). Although no gross de-
fect  in  myeloid  or  lymphoid  development  in  bic-deficient 
m i c e  w a s  o b s e r v e d ,  p r o t e c t i v e  i m m u n i t y  d i d  a p p e a r  t o  b e  
impaired. After intravenous immunization with live attenuated 
form of the enteric pathogen Salmonella typhimurium (aroA 
mutant strain), mice were assessed for their ability to resist 
oral challenge with virulent S. typhimurium (59). Unvaccinat-
ed  bic
m2/m2mice  were  less  readily  protected  by  aroA  vacci-
nation, and the majority of mice succumbed to challenge with 
the virulent strain by 33 days after infection. Thus, immunized 
bic-deficient mice, unlike wild-type mice, could not be pro-
tected  by  immunization  to  this  pathogen  (59).  Turner  and 
Vigorito  showed  that  bic-deficient  mice  were  immuno-
deficient and failed to generate high levels of class-switched 
antibody  upon  immunization  with  thymus-dependent  and 
thymus-independent antigens (174). In addition, bic-deficient 
T-cells  showed  skewed  differentiation  into  the  Th2  lineage 
under a variety of in vitro culture conditions. Microarry analy-
sis of bic-deficient B- and T-cells under different conditions 
has  revealed  a  wide  spectrum  of  targets  regulated  by  an 
miR-155 and has suggested mechanisms for the regulation of 
lymphocyte  differentiation  by  a  single  miRNA  (174).
    Using genetic deletion and transgenic approaches, Thai et 
al. showed that the evolutionarily conserved miRNA-155 has 
an important role in the mammalian immune system, specifi-
cally in regulating T helper cell differentiation and the germi-
nal  center  reaction  to  produce  an  optimal  T-cell-dependent 
antibody response (176). miR-155 exerts this control, at least 
in part, by regulating cytokine production. These results also 
suggest that individual miRNAs can exert critical control over 
mammalian  differentiation  processes  in  vivo  (176).  DNA 
methyltransferase Dnmt1 and DNA methylation are required 
for the proper expression of certain genes that define fate and 
determine function in T-cells (181). Banerjee et al. reported 
that CD4＋ T-cells lacking miR-155 exhibit bias towards Th2 
differentiation,  indicating  that  the  absence  of  individual 
miRNA  could  alter  CD4＋ T-cell  differentiation  (182).  They 
also showed that miR-155 induces upon T-cell activation and 
that it promotes Th1 differentiation when over-expressed in 
activated  CD4＋ T-cells  by  inhibiting  IFN-γ signaling. 
    Neilson  et  al.  observed  that  individual  miRNAs  were  dy-
namically regulated during T-cell development, with at least 
one miRNA or miRNA family overrepresented at each devel-
opmental  stage,  and  that  miRNA  regulation  in  this  devel-
opmental  pathway  is  characterized  by  analog  rather  than 
switch-like  behavior,  with  temporal  enrichments  at  distinct 
stages of development observed against a background of con-
stant  and  basal  expression  of  the  miRNA  (183).  miR-181a, 
which is specifically enriched at the CD4＋CD8＋ (DP) stage 
of  thymocyte  development,  can  repress  the  expression  of 
Bcl-2, CD69, and the T-cell receptor, all of which are coordin-
ately involved in positive selection (183). T-cell sensitivity to 
antigen is intrinsically regulated during maturation to ensure 
proper development of immunity and tolerance. Li et al. ob-
served that increasing miR-181a expression in mature T cells 
augmented the sensitivity to peptide antigens, while inhibiting 
miR-181a expression in the immature T-cells reduced sensi-
tivity and impaired both positive and negative selection (158). 
Moreover,  they  found  that  quantitative  regulation  of  T  cell 
sensitivity by miR-181a enabled mature T cells to recognize 
antagonist  -  the  inhibitory  peptide  antigens  -  as  agonists. 
Importantly,  higher  miR-181a  expression  correlated  with 
greater  T-cell  sensitivity  in  immature  T-cells,  indicating  that 
miR-181a acts as an intrinsic antigen sensitivity "rheostat" dur-
ing  T-cell  development  (158).
    Interestingly, Johnston et al. found that expression of the 
transcription factor Bc16 in CD4＋ T-cells is both necessary 
and sufficient for the in vivo differentiation of follicular helper 
T-cells (Tfh) and T-cell assistance of B-cells in mice. In con-
trast, the transcription factor Blimp-1, an antagonist of Bc16, 
inhibits Tfh differentiation and help, thereby preventing B-cell 
germinal center and antibody responses (184). These findings 
demonstrate that Tfh cells are required for proper B-cell re-
sponses in vivo and that Bc16 and Blimp-1 play central, but 
opposing,  roles  in  Tfh  differentiation.
miRNAs IN TREG CELLS
The discovery of miRNA is one of the major recent scientific 
breakthroughs  and  has  revolutionized  knowledge  of  gene 
regulation. Although we are still at a very early stage in un-
derstanding their impact of immunity, miRNAs are changing 
the way we think about the development of the immune sys-
tem  and  regulation  of  immune  functions  (35,56,185,186). MicroRNAs in Regulatory T Cells and Immune Response
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miRNAs are critical for a number of aspects of immune sys-
tem regulation and function. As mentioned, miRNA are small 
untranslated RNA species, which have been implicated in the 
regulation  of  gene  expression  essential  for  organ  develop-
ment,  cellular  differentiation,  homeostasis,  and  functioning 
through target mRNA degradation or translational interference 
(31,35,56,57).  To  gain  functional  evidence  of  the  role  of 
miRNA in Treg cell biology, Liston et al. (85) and Zhou et 
al. (86) recently developed mouse models by depleting Dicer 
specifically in Foxp3 Treg cell lineage either using mice with 
Foxp3Cre knock-in allele (85) or Foxp3 GFP-hCre transgenic 
mice (86). Both mice showed progression of fatal early onset 
lymphoproliferative  autoimmune  syndrome  during  the  third 
week of life, indistinguishable from that observed in Foxp3 
mutant  mice  devoid  of  Treg  cells  (84,85,87).  Although 
miRNA-mediated gene expression is critical during B-cell dif-
ferentiation (162), depletion of miRNA in developing thymo-
cytes does not result in a gross perturbation of T-cell differ-
entiation  (163,164).  Dicer  deletion  early  in  T-cell  develop-
ment induced by a Cre transgene driven by the lck promotor, 
lckCre, expressed from the double-negative (DN) 2 stage on-
ward,  resulted  in  a  sharp  reduction  of  miRNAs  by  the  DP 
stage and a 10-fold drop in the number of TCR-αβ thymo-
cytes (163,181). However, Cobb et al. (87) and Chong et al. 
(84)  reported  that  ablation  of  either  Dicer  or  Drosha,  two 
RNase  III  enzymes  critical  for  the  generation  of  mature 
miRNAs, at a stage of the DP thymocyte differentiation, re-
duces  the  numbers  of  Foxp3＋ thymocytes  and  peripheral 
Treg  cells  and  immune-mediated  lesions  that  develop  at 
6-mohths-of-age) (84,87). Likewise, Cobb et al. reported a re-
duction in the efficiency of Foxp3 induction upon stimulation 
of  naive  Dicer-deficient  T-cells  in  the  presence  of  TGF-β 
(87).
    Importantly, Dicer-deficient Treg cells lose suppression ac-
tivity  in  vivo.  As  described  earlier,  in  addition  to  Dicer, 
Drosha  is  another  RNAseIII  enzyme  related  to  miRNA  bio-
genesis (35,84,131,132). By genetic ablation of Drosha within 
t h e  T  c e l l  c o m p a r t m e n t  o r  s p e c i f i c a l l y  w i t h i n  F o x p 3 ＋Treg 
cells, Chong et al. found that, like the Dicer deletion, deletion 
of Drosha in Treg cells phenocopies mice lacking a functional 
Foxp3  gene,  which  further  confirmed  the  critical  role  of 
miRNA-dependent  regulation  in  Treg  cell  development  and 
function,  and  in  preventing  spontaneous  inflammation  and 
autoimmunity  (84).  The  functional  impairment  of  effector 
T-cells in CD4Cre-Dicer knockout mice is probably the main 
reason of the much milder disease found in the CD4Cre-Dicer 
knockout mouse strain compared to Foxp3Cre-Dicer knock-
out mice (85,86,163,164). Zheng et al. suggested a potential 
role  of  miR-155  in  Treg  cell  formation  or  function  (187). 
Interestingly,  a  genome-wide  analysis  combining  chromatin 
immunoprecipitation with mouse genome tiling array profil-
i n g  i d e n t i f i e d  F o x p 3  b i n d i n g  r e g i o n s  f o r  a p p r o x i m a t e l y  7 0 0 
genes and for an intergenically encoded miRNA (187). The 
s a m e  s t u d y  r e p o r t e d  t h a t  a  l a r g e  n u m b e r  o f  F o x p 3 - b o u n d  
genes are up- or down-regulated in Foxp3＋ T cells, suggest-
ing  that  Foxp3  acts  as  both  a  transcriptional  activator  and 
repressor.
    Liston et al. reported that miR-155-deficient Treg cells ex-
hibit  impaired  homeostasis  and  proliferative  potential,  but 
keep the largely intact in vitro and in vivo suppression func-
tions,  suggesting  that  distinct  miRNA  species  might  control 
different facets of the Dicer-dependent Treg cell phenotype 
(85). Consistent with the aforementioned observations, using 
both  Tie2Cre-  and  CD4Cre-mediated  Dicer  deletion  mouse 
models, Zhou et al. (188) also observed that lack of miRNAs 
at both stages results in a 2-3-fold decrease in the proportion 
of Foxp3 Treg cells. These studies have clearly demonstrated 
a role for miRNA-dependent regulation in the thymic develop-
ment of CD4＋CD25＋Foxp3＋ Treg cells. However, a gen-
eral impairment in thymic differentiation observed upon Dicer 
deletion  at  the  hematopoietic  stem  cell  and  early  or  later 
T-cell developmental stages mediated by Tie2Cre, IckCre, or 
CD4Cre obscures the understanding of a specific role for the 
Dicer-controlled  miRNA  pathway  in  Treg  cell  development 
and function. Liston et al. (85) found that Dicer deficient Treg 
cells  showed  impaired  peripheral  homeostasis  and  that 
Dice-deficient Treg cells from healthy mice were anergic and 
functional (namely, unable to proliferate in response to TCR 
stimulation, retaining this distinguishing feature of wild-type 
Treg cells), although the cells were markedly less efficient on 
a per cell basis compared with the Dicer-sufficient Treg cells 
isolated from their wild-type counterparts, similar with that of 
Treg  cells  isolated  from  CD4Cre-Dicer  deletion  mice  (85). 
However, Dicer-deficient Foxp3＋ T cells purified from litter-
mates under conditions of inflammation were completely de-
void of suppressor activity and  instead showed a robust  in 
vitro proliferative response consistent with the identical auto-
immune syndrome in these mice (85). The authors further ob-
served the decreased expression of putative suppressor mole-
cules,  including  CTLA4,  ICOS,  IL-10,  EBV-induced  gene  3 
(EBi3),  granzyme  B,  and  CD73  in  Dicer  deficient  Foxp3＋ 
Treg cells, in agreement with their marked impairment in sup-MicroRNAs in Regulatory T Cells and Immune Response
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pressor  capacity.  Interestingly,  the  Dicer-deficient  Foxp3＋
Treg cells showed comparable Foxp3 mRNA and protein lev-
els  with  their  wild-type  counterpart,  supporting  the  notion 
t h a t  t h e  l o s s  o f  s u p p r e s s i v e  c a p a c i t y  w a s  n o t  c a u s e d  b y  
changes in Foxp3 itself, but rather by low expression of sup-
pressor  effecter  molecules  (85).  In  contrast,  with  a  Foxp3- 
GFP-hCre transgenic Treg-specific Dicer deletion mouse mod-
el, Zhou et al. (86) showed that mice deleted of Dicer at the 
time of Foxp3 expression displayed an interrupted Treg cell 
lineage  stability  based  on  their  down-regulated  Foxp3  ex-
pression, which positively correlated with mouse age, even 
though the mice showed normal thymic Treg cell develop-
ment at 2-weeks-of-age (86). Moreover, microarray studies al-
so indicated that the majority of Treg cells from Foxp3Cre- 
Dicer  knockout  mice  expressed  altered  levels  of  multiple 
genes and proteins, largely consistent with a previous study 
(85),  and  a  significant  percentage  take  on  a  T  helper  cell 
memory phenotype with increased levels of CD127, IL-4, and 
IFN-γ (86). Cobb et al. also reported that Treg cells have 
a miRNA profile distinct from conventional CD4 T-cells and 
that a partial Treg cell-like miRNA profile is conferred by the 
enforced expression of Foxp3 and, surprisingly, by the activa-
tion of conventional CD4 T-cells (87). Depleting miRNAs by 
eliminating  Dicer  reduces  Treg  cell  numbers  and  results  in 
immune  pathology  (87).  Dicer  facilitates,  in  a  cell-autono-
mous fashion, the development of Treg cells in the thymus 
and the efficient induction of Foxp3 by TGF-β (87). These 
results suggest that Treg cell development involves Dicer-gen-
erated RNAs. Interestingly, the dataset of the study was sub-
jected to significance analysis of microarrays (SAM). Impor-
tantly,  the  authors  demonstrated  that  SAM  identified  68 
miRNAs  that  were  differentially  expressed  between  nTreg 
cells and conventional CD4＋CD25- T-cells. The authors also 
showed that 35 miRNAs were preferentially expressed in Treg 
cells  (including  miR-223,  miR-146,  miR-21,  miR-22,  miR-23a 
and b, miR-24, miR-214, miR-155, and others) and 33 were 
down-regulated in Treg cells (including miR-142-5p and -3p, 
miR-30b, c, e, and members of the Let-7 family). Interestingly, 
in the same study, the ectopic expression of the Treg cell sig-
nature Foxp3 conferred a partial Treg cell miRNA profile (87). 
Hence, aspects of the Treg cell-specific miRNA profile may 
be under the direct or indirect control of Foxp3. In addition 
to the extensive overlap between the miRNA profile of Treg 
cells  and  activated  T-cells,  their  analysis  has  identified 
miRNAs that are overexpressed by Treg cells but not by acti-
vated  T-cells,  for  example  miR-223  and  miR-146  (87).  The 
thymic differentiation of nTreg cells was compromised in the 
absence  of  Dicer  and  mature  miRNAs.
    Despite a role of miRNA in the generation of Foxp3＋Treg 
cells both in the thymus and in the periphery, it seems un-
likely  miRNAs  are  involved  in  the  regulation  of  Foxp3 
production. Three studies found no evidence in Treg cells in 
mice with a T-cell specific or Treg-specific Dicer or Drosha 
deletion (84,85,87). However, Zhou et al. (86) reported that, 
upon  deletion  of  a  conditional  Dicer  allele  mediated  by  a 
Foxp3 BAC transgene encoding YFP-Cre, a significant promo-
tion of Dicer-deficient Treg cells became Foxp3 negative, im-
plicating  miRNA  in  Treg  lineage  stabilization.  Furthermore, 
Liston et al. (85) reported that the miRNA pathway also pro-
moted survival and proliferative potential of Treg cells, similar 
to  its  role  in  T-  and  B-cell  lineages.
    In  addition  to  its  role  in  Treg  development  and  homeo-
stasis, miRNA-dependent regulation of gene expression is also 
critical  to  controlling  Treg  cell  function.  It  is  interesting  to 
note that depletion of miRNA within the Treg cell lineage can 
result in a fatal autoimmunity indistinguishable from that in 
Treg cell-deficient mice (84-86). Interestingly, the suppressor 
capacity of Dicer-deficient Treg cells was maintained, albeit 
at  a  markedly  reduced  level,  under  noninflammatory  con-
ditions (84-86). However, Liston  et  al.  (85) showed that in 
inflammatory settings, these cells entirely lost the suppressor 
capacity  despite  a  marked  increase  in  their  numbers  and 
activation. These observations may implicate miRNAs as key 
guardians  of  a  stable  Treg  suppressor  program  under  in-
flammatory  conditions.
    Treg-specific Dicer and Drosha ablation studies have raised 
a  question  as  to  the  identity  of  specific  miRNAs  regulating 
distinct aspects of Treg cell biology. Cobb et al. first demon-
strated differential miRNAs expression in Foxp3＋ Treg cells 
in  2006  (87).  Furthermore,  many  Treg-specific  miRNAs  are 
expressed  in  Treg  cells  in  a  Foxp3-dependent  manner. 
Among  the  Foxp3-dependent  miRNAs,  miR-155  is  directly 
regulated  by  Foxp3  (98,151,187).  Although  dispensable  for 
Treg  differentiation  and  suppressor  function,  Foxp3-driven 
m i R - 1 5 5  u p - r e g u l a t i o n  i s  c r i t i c a l  f o r  h e i g h t e n e d  r e s p o n s i v e -
ness of Treg cells to their key survival and growth factor, IL-2. 
  At a mechanistic level, miR-155-mediated control of Treg cell 
homeostasis  is  mediated  through  the  targeting  of  SOCS1,  a 
negative regulator of IL-2 signaling. Thus, constitutively high 
expression  of  miR-155  driven  by  Foxp3  ensures  efficient 
STAT5 phosphorylation in the presence of limiting amounts 
of IL-2 and, thus, fitness of Treg cell subset in a competitive MicroRNAs in Regulatory T Cells and Immune Response
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environment  (151).  This  finding  not  only  provides  the  first 
example of a single miRNA controlling Treg homeostasis but 
also demonstrates that different miRNAs affect distinct facets 
of Treg cell biology. Treg cells limit the pathogenic immune 
response to self-antigens and foreign antigens. An essential 
role  for  miRNA  in  the  maintenance  and  functions  of  Treg 
cells, revealed by the Treg cell-specific Dicer ablation, raises 
a question as to a specific miRNA contribution. Lu et al. (151) 
found that Foxp3 controlled the elevated miR-155 expression 
r e q u i r e d  f o r  m a i n t a i n i n g  T r e g  c e l l  p r o l i f e r a t i v e  a c t i v i t y  a n d  
numbers under nonlymphopenic conditions. Moreover, they 
a l s o  f o u n d  t h a t  m i R 1 5 5  d e f i c i e n c y  i n  T r e g  c e l l s  r e s u l t e d  i n 
increased SOCS1 expression accompanied by impaired activa-
tion  of  STAT5  transcription  factor  in  response  to  limiting 
amounts of IL-2. Their study suggests that Foxp3-dependent 
regulation  of  miR-155  maintains  the  competitive  fitness  of 
Treg  cells  by  targeting  SOCS1,  and  provides  experimental 
support for a proposed role for miRNAs in ensuring the ro-
bustness of cellular phenotypes (151). This finding not only 
provides the first example of a single miRNA controlling Treg 
homeostasis but also demonstrates that different miRNAs af-
fect  distinct  facets  of  Treg  cell  biology.
    Lu  et  al.  (151)  provided  experimental  evidence  showing 
that: 1) Foxp3 regulates miR-155 expression in Treg cells, 2) 
miR-155 deficiency results in a reduction of Treg cell num-
bers, 3) diminished proliferative potential of miR155-deficient 
Treg  cells,  4)  miR-155  maintains  competitive  fitness  of  Teg 
cells,  5)  attenuated  IL-2  signaling  in  miR-155-deficient  Treg 
cells, and 6) miR-155 maintains Treg cell homeostasis by lim-
iting SOCS1 protein expression; SOCS 1 protein amounts are 
low in miR-155-sufficient Treg cells. In contrast, miR-155-defi-
cient  Treg  cells  exhibit  an  approximately  5-fold  increase  in 
the amount of SOCS1 (151). Recently, Kohlhass et al. (189) 
investigated the contribution of miR-155 to Treg development 
and function. They reported that mice deficient in bic/miR155 
showed  reduced  numbers  of  Treg  cells  in  the  thymus  and 
spleen. They also found that Treg cell development required 
bic/miR155,  but  that  it  was  dispensable  for  Treg  cell  pro-
liferation or survival in the periphery. Despite the lower num-
bers of Treg cells, their suppressor function in vitro remained 
intact.  Furthermore,  no  signs  of  spontaneous  inflammatory 
bowel  disease  (IBD)  were  observed  in  young  or  aged 
miR-155-deficient mice, and miR-155-deficient CD4＋CD25＋ 
T cells were able to prevent colitis induced by the adoptive 
transfer of CD4＋CD45RB
high T cells into lymphopenic hosts 
(189). The results indicate that miR-155 contributes to Treg 
cell  development,  but  its  absence  does  not  overtly  com-
promise  Treg  function  in  vitro a n d  in  vivo.
    Human umbilical cord blood (UCB) contains a distinct pop-
ulation of CD25＋Treg cells that are less heterogeneous than 
in adult peripheral blood. Indeed, except for fetal infection, 
the majority of human cord blood CD4＋CD25＋ T cells ex-
press Foxp3 (190). Thus, cord blood is a convenient source 
for studies aimed at understanding human nTreg, because, in 
contrast  to  adult  blood,  as  they  are  less  contaminated  by 
CD25
＋-activated non-Treg T cells. Moreover, while Foxp3 ex-
pression is not sufficient to identify Treg cells in adult human 
blood,  it  remains  a  marker  of  choice  in  UCB  lymphocytes 
from  healthy  newborns  and  in  adult  peripheral  blood  Treg 
cells  provided  they  are  distinguished  from  activated  T  cells 
(190). miRNAs signatures have been described in mouse Treg 
cells (84-87,191). Studies in humans have been done to iden-
tify a human miRNA Treg signature in healthy volunteers and 
patients (186,190,192-195). Very recently, Redouane et al. in-
vestigated human nTreg  using UCB  (190)  and identified 10 
miRNAs that were differentially expressed between nTreg and 
naive  CD4＋CD25＋ T  cells.  Eight  miRNAs  were  preferen-
tially  expressed  in  nTreg  (miR-425-Sp,  miR-181c,  miR-21, 
miR-374, miR-586, miR-340, miR-26b, and miR-491) and two 
were  selectively  down-regulated  in  nTReg  (miR-31  and 
miR-125a) using the TaqMan Low Density Array (TLDA) tech-
n i q u e  ( 1 9 0 ) .  D i f f e r e n t i a l  m i R N A  e x p r e s s i o n  w a s  t h e n  v a l i -
dated by real-time PCR. A nTreg miRNA signature was de-
fined,  consisting  of  five  statistically  differentially  expressed 
miRNAs (miR21, miR-31, miR-125a, miR-181c, and miR-374). 
These miRNAs were detected using the TLDA technique and 
confirmed  by  quantitative  PCR  (190).  Three  of  the  five 
miRNAs  were  over-expressed  (miR-21,  miR-181c,  and  miR- 
374)  and  the  remaining  two  were  under-expressed  (miR-31 
and  miR-125a).  They  also  identified  a  functional  target  se-
quence for miR-31 in the 3’UTR of Foxp3 mRNA (190). Using 
lentiviral transduction of fresh cord blood T cells, the authors 
demonstrated  that  miR-31  negatively  regulated  Foxp3  ex-
pression by binding directly to its potential target site in the 
3’UTR of Foxp3 mRNA (190). The authors also demonstrated 
that miR-21 acted as a positive, though indirect, regulator of 
Foxp3  expression.  Transduction  of  the  remaining  three 
miRNAs had no direct effect on Foxp3 expression or on the 
phenotype and will remain the subject of future investigation. 
Taken together, the study not only found and validated a miR 
signature for human nTreg for the first time, but also unveiled 
some of the mechanisms by which this signature may be in-MicroRNAs in Regulatory T Cells and Immune Response
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volved in the control of the Foxp3 levels in nTreg. This opens 
several possibilities for the future, i.e. to qualitatively inves-
tigate induced Treg in several circumstances, healthy volun-
teers, and patients suffering from cancer and immune disor-
ders. These experiments, coupled with quantitative measure-
ments in these different situations, could provide new insights 
into the defective immune response in malignancies, immune 
disorders,  infections  and  transplantation.
  Hussein et al. reported that histone deacetylase inhibitors 
increased Foxp3 expression in T cells (192). They therefore 
decided  to  investigate  in  non-Treg  CD4-positive  cells  the 
mechanisms by which an a specific opening of the chromatin 
could lead to an increased Foxp3 expression. They focused 
on binding of potentially activating transcription factors to the 
promoter region of Foxp3 and on modifications in the five 
miRNAs constituting the Treg cell signature. Valproate treat-
ment  also  induced  binding  of  E-twenty  six  family-1  (Ets-1) 
and Ets-2 to the Foxp3 promoter and acted positively on its 
expression, by increasing the acetylation of histone H4 lysines 
(192).  Vaproate  also  induced  the  acquisition  of  the  miRNA 
Treg cell signature (192). To elucidate whether the changes 
in the miRNA expression could be due to the increased Foxp3 
expression, the authors transduced these non-Treg cells with 
a Foxp3 lentiviral expression vector, and found no changes 
in  miRNA  expression.  Therefore,  the  modification  in  their 
miRNA  expression  profile was not due  to  an increased  ex-
pression of Foxp3 but resulted directly from histone deacety-
lase inhibition. Rather, the increased Foxp3 expression results 
from the additive effects of Ets factor binding to its promoter, 
and  the  change  in  expression  level  of  miR-21  and  miR-31. 
The  authors  noted  that  valproate  treatment  of  human  non- 
Treg cells confers a molecular profile similar to that of their 
regulatory  counterparts  (192).  Their  findings  strongly  sug-
gested  that  valproate  treatment  increases  Foxp3  mRNA  and 
protein  levels  in  CD4＋,  CD25-  T  cells  and  that  val-
proate-treated UCB CD4＋, CD25-T cells transiently adopt a 
nTreg miRNA expression signature. Taken together, the data 
indicate  that  CD4＋C D 2 5 - U C B  T  c e l l s  t r a n s i e n t l y  a d o p t  a  
nTreg  cell-like  miRNA  signature  upon  valproate  treatment 
(high  Foxp3  expression,  low  miR-31  and  miR-125a  ex-
pression, and high level of miR-21, miR-181c, and miR-374). 
Ets1  and  Ets-2  stimulate  the  Foxp3  promoter.
  Xiao et al. reported the requirement of Treg cells for the 
maintenance of immune homeostasis and that dysfunction of 
Treg cells leads to fatal autoimmunity in humans and mice 
(30).  Conversely,  the  activation  of  different  classes  of  Treg 
cells  operative  systemically  and  within  the  cancer  micro-
environment can suppress host anti-tumor immune responses 
and promote tumor progression. Therefore, the development 
of new therapeutic approaches to regulate the activity of Treg 
cells  may  have  considerable  clinical  potential.  It  is  well- 
known that Foxp3 is a key transcriptional regulator of Treg 
development and function (14). The activity of Foxp3 is regu-
lated by acetylation, a process catalyzed distinct types of his-
tone/protein acetyltransferases (HATs) that regulate the func-
tions of many transcription factors, independent of Foxp3, as 
well as non-histone proteins, in addition to their effects on 
chromatin accessibility (30). Interactions between Foxp3 and 
these enzymes determine the suppressive function of Foxp3. 
Clearly, small molecules targeting these enzymes are candi-
dates for the regulation of Treg function in vaccines and tu-
mor  therapies  (30).
    Multiple sclerosis (MS) is a chronic inflammatory response 
against  constituents  of  the  CNS.  Treg  cells  play  a  key  role 
in the autoimmune balance and their improper function may 
f a c i l i t a t e  t h e  e x p a n s i o n  o f  a u t o a g g r e s s i v e  T  c e l l  c l o n e s  
(13,66).  Involvement  of  miRNAs  in  autoimmune  disorders 
and their loss-of-function in immune cells facilitates systemic 
autoimmune disorders (66,99). De Santis et al. (143) found 
23  human  miRNAs  differentially  expressed  between  CD4＋
CD25
high bona fide Treg cells from MS patients versus healthy 
donors,  but,  conversely,  among  the  deregulated  miRNAs, 
members of the miR-106b-25 were found down-regulated in 
MS  patients  when  compared  to  healthy  donors  in  CD4＋
CD25
highCD127
dim/− T r e g  c e l l s .  M o r e  i n t e r e s t i n g l y ,  t h e  r a t i o  
between Treg/Teff showed an enrichment of these miRNA in 
Treg cells derived from patients if compared to healthy con-
trols (143). The data suggested that the abnormal expression 
of miRNA in Treg cells might play a role in the pathogenesis 
of  MS.
    Cobb et al. raised a question as to how individual miRNAs 
present in increased amounts in Treg cells contribute to dis-
tinct aspects of their homeostasis and function (87). Recently, 
it has been reported that miR-155, a well-known onco-miRNA 
(cancer-associated miRNA), is constitutively expressed in high 
amounts in Treg cells in a Foxp3-dependent manner, whereas 
T  cells  lacking  Foxp3,  B  cells,  and  myeloid  cells  are  tran-
siently  up-regulated  miR-155  upon  activation  (149,155,176). 
Lu  and  Rudensky  (196)  also  reported  that  miR-155  confers 
heightened responsiveness of Treg cells to their key survival 
and growth factor, IL-2, thereby maintaining their numbers in 
a competitive environment. However, miR155 is largely dis-MicroRNAs in Regulatory T Cells and Immune Response
Tai-You Ha
29 IMMUNE NETWORK http://www.ksimm.or.kr Volume 11 Number 1 February 2011
pensable  for  Treg  suppressor  function  (196).
    Like miR-155, miR-146a is highly expressed in Treg cells. 
It  has  been  demonstrated  that  miR-146a,  which  is  up-regu-
lated during viral infection, is a negative regulator of the reti-
noic acid-inducible gene (RIG)-I-dependent antiviral pathway 
by targeting TRAF6 (TNFR-associated factor), IRAK1 (IL-1R-as-
sociated  kinase  1),  and  IRAK  2  (153,154).  Curtale  et  al. 
showed that miR-146 is low in human naive T cells and is 
abundantly expressed in human memory T cells (169). They 
also  showed  that  miR-146a  modulated  activation-induced 
death domain (AICD) by acting as an antiapoptotic factor and 
that FADD is a target of miR-146. Furthermore, they demon-
strated that miR-146a enforced expression impairs both activa-
tor protein 1 (AP-1) activity and IL-2 production induced by 
TCR engagement. More recently, Lu et al. (197) explored a 
role for miR-146a in Treg cells and reported that miR-146a, 
which is prevalently expressed in Treg cells, is essential for 
the  ability  of  Treg  cells  to  restrain  IFN-γ-mediated  patho-
genic Th1 responses and associated inflammation. They also 
found that in Treg cells, miR-146a-mediated down-regulation 
of STAT1, a key transcription factor required for Th1 effector 
cell differentiation, was necessary for Treg cell ability to sup-
press  Th1  response.  Likewise,  heightened  STAT1  activation 
in Treg cells subjected to a selective ablation SOCS1, a key 
negative regulator of STAT1 phosphorylation downstream of 
the  IFN-γ receptor,  was  associated  with  analogous  Th1- 
mediated pathology (197). Furthermore, they found that re-
lieving negative regulation of STAT1 activation in Treg cells 
using  an  alternative  genetic  approach  resulted  in  a  break-
down of immune homeostasis similar to that observed in mice 
harboring  miR-146a-deficient  Treg  cells.  Thus,  their  results 
suggest that specific aspects of Treg cell suppressor function 
are controlled by a single miRNA and that an optimal range 
of STAT1 activation is important for Treg-mediated control of 
Th1  responses  and  associated  autoimmunity.
    The generation of mice with a conditional deletion of Dicer 
or  Drosha  in  Treg  cells  has  shown  a  requirement  for  the 
miRNA pathway in Foxp3＋Treg cells (84-86,151,189). These 
mice develop a lethal autoimmune inflammatory disease, con-
sistent with impaired development or function of Treg cells 
homeostasis  and  overall  survival,  and  this  is  thought  to  in-
volve the direct targeting of SOCS1 (151,189). However, be-
cause the absence of miR-155 did not reproduce the severe 
disease  that  occurs  in  mice  with  a  conditional  deletion  of 
Dicer, additional miRNAs are probably involved in Treg cell 
biology.  Several  other  miRNAs  are  expressed  by  Treg  cells 
and  await  functional  assessment  (87,186,193).
    Phosphodiesterases,  the  enzyme  that  accelerate  the  turn-
over of cAMP, are up-regulated in activated helper T cells and 
down-regulated in Treg cells (98,187). Interestingly, Huang et 
al. showed that miR-142-3p regulates the production of cAMP 
by targeting adenyl cyclase (AC) 9 mRNA in CD4＋CD25- T 
cells  and  CD4＋CD25＋ Treg  cells  (191).  Moreover,  they 
showed that miR-142-3p limits the level of cAMP in CD4＋
CD25- T cells by inhibiting AC9 production, whereas Foxp3 
down-regulates miR-142-3p to keep the AC9/cAMP pathway 
active  in  CD4＋CD25＋ Treg  cells.  These  findings  reveal  a 
new  molecular  mechanism  through  which  CD4＋CD25＋ 
Treg cells contain a high level of cAMP for their suppressor 
function, and also suggest that the miRNA controlling AC ex-
pression might restrict the final level of cAMP in various types 
of  cells.  Interestingly,  Bopp  et  al.  reported  that  the  sup-
pressive activity of nTreg cells is abolished by a cAMP antago-
nist as well as by a gap junction inhibitor, suggesting an un-
expected role for a classical second messenger in combina-
tion with an ubiquitous system of intercellular communication 
i n  n T r e g  c e l l - m e d i a t e d  s u p p r e s s i o n  ( 1 9 8 ) .  O f  n o t e ,  t h e  e x -
pression of miR-142-3p was recently shown to be repressed 
by Foxp3, leading to increased production of cyclic AMP and 
suppressor  function  of  Treg  cells  (191).
  Asirvatham et al. studied 613 genes that regulate immunity 
and  identified  285  genes  as  miRNA  targets  (199).  Interest-
ingly, they found that major targets include transcription fac-
tors, cofactors and chromatin modifiers upstream factors, such 
as  ligand  and  receptors  (cytokines,  chemokines  and  TLRs) 
were, in general, non-targets. About 10% of immune genes 
were  ‘hubs’  with  eight  or  more  different  miRNAs  predicted 
to target 3’UTRs. Hubs were focused on certain key immune 
genes, such as BCL6, SMAD7, BLIMPT, NFAT5, EP300, and 
others (199). Moreover, multiple components involved in the 
generation  and  effector  functions  of  miRNAs  (Dicer  and 
Argonautes) were themselves miRNA targets suggesting that 
a  subset  of  miRNA  may  indirectly  control  their  own  pro-
duction  as  well  as  other  miRNAs  (199).
    Treg cells are the main mediators of dominant tolerance. 
Their mechanisms of action and applications are subjects of 
considerable debate currently. Rouas et al. (193) investigated 
human  nTReg  and  identified  a  signature  composed  of  five 
miRNA (miR-21, miR-31, miR-125a, miR-181c, and miR-374). 
Among those, two were considerably under-expressed (miR- 
31 and miR-125a). The authors also identified a functional tar-
get sequence for miR-31 in the 3’UTR of Foxp3 mRNA. Using MicroRNAs in Regulatory T Cells and Immune Response
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lentiviral transduction of fresh cord blood T cells, the authors 
demonstrated  that  miR-31  and  miR-21  affected  Fosp3  ex-
pression by binding directly to its potential target site in the 
3’UTR of Foxp3 mRNA. Additionally, they demonstrated that 
miR-21  acted  as  a  positive,  although  indirect,  regulator  of 
Foxp3  expression.
  R e c e n t  s t u d i e s  s u g g e s t  a  r o l e  f o r  D i c e r  a n d  D r s h a - c o n -
trolled miRNA pathways in Treg cell-mediated immune toler-
ance (84-87) and of miRNAs in the development and function 
of Treg cells (86,189). Treg cells from normal animals display 
a  specific  miRNA  profile  (84-87).  However,  it  is  unclear 
whether Dicer and miRNAs play a role in eliciting Treg cell 
defect  in  humans  and  mice  with  autoimmune  disease  such 
as systemic lupus erythematosus (SLE). SLE is a chronic auto-
immune disease characterized by loss of tolerance to self-anti-
gens  and  activation  of  autoreactive  T  cells.  Treg  cells  play 
a critical role in controlling the activation of autoreactive T 
cells. More currently, Divekar et al. (186) investigated mecha-
nisms of potential Treg cell defect in SLE using MRL-Fas
lpr/lpr 
(hereafter  referred  to  as  MRL/lpr)  and  congenic  Fas-intact 
MRL-Fas
＋/＋ ( M R L
＋/＋)  mouse  models.  Paradoxically,  they 
found  that  a  significant  increase  in  CD4＋CD25＋Foxp3＋ 
Treg cells, albeit with an altered phenotype and with a re-
duces suppressive capacity, in the lymphoid organs of MRL 
strains, and a profound reduction in Dicer expression and an 
altered miRNAs profile in MRL/lpr Treg cells. Despite having 
a reduced level of Dicer, MRL/lpr Treg cells exhibited a sig-
nificant  overexpression  of  several  miRNAs,  including  let-7a, 
let  7f,  miR-16,  miR-23a,  miR-23b,  miR27a,  and  miR-155. 
Surprisingly,  autoimmune  disease  development  in  MRL/lpr 
mice was associated with significantly increased miR-155, de-
spite a profound reduction in Dicer expression (186). They 
also demonstrated the first example of an acquired deficiency 
of  Dicer,  which  occurs  spontaneously  in  MRL/lpr  mice  just 
prior to the onset of inflammatory disease. Thus, genetic defi-
ciency of Dicer in knockout mice as well as its acquired defi-
ciency in MRL/lpr mice is associated with Treg abnormalites 
and development of autoimmune disease, suggesting an im-
portant role of Dicer in Treg cell function and prevention of 
a u t o i m m u n i t y  ( 1 8 6 ) .  I n d e e d ,  t h e  D i c e r - c o n t r o l l e d  m i R N A  
pathway is important in the control of autoimmunity (84-87). 
Using computational and experimental approaches, Divekar 
et al. further identified miR-155 as regulating an altered phe-
notype of Treg cells in SLE (186). Together, these data sug-
gest a role of Dicer and miR-155 in conferring Treg cell defect 
in  SLE.  Furthermore,  simultaneous  appearance  of  Dicer i n -
sufficiency and miR-155 over-expression in disease mice sug-
gests a Dicer-independent alternative mechanisms of miRNA 
under inflammatory conditions (186). In Treg cells of diabetic 
patients,  interestingly,  Hezova  et  al.  found  significantly  in-
creased expression of miRNA-510 and decreased expression 
of both miRNA-342 and miRNA-191 (194). When comparing 
Treg cells and T cells, it was revealed that Treg cells had sig-
nificant higher expression of miR-146a and lower expression 
of eight specific miRNAs (20b, 31, 99a, 100, 125b, 151, 335, 
and 365). This may be the first study demonstrating changes 
in miRNA expression profiles occurring in Treg cells of type 
1  diabetic  patients  and  a  miRNAs  of  adult  Treg  cells.
    Freier et al. analyzed the behavior of Treg cells in the con-
text of a stress-induced activation of the adaptive immune re-
sponse in healthy young males (195). The authors found that 
acute psychological stress caused a concomitant decrease in 
CD4＋FOXP3 Treg cells and in CD4＋ T cells expressing Treg 
cell-related effector molecules CTLA-4 and latency associated 
peptide (LAP). In addition, they observed β1-adrenergic and 
glucocorticoid α receptor to be over-expressed in Treg cells, 
suggesting that these molecules might mediate stress-related 
effects on Treg cells (195). It has been reported that inhibiting 
components  of  the  adaptive  immune  response,  like  Treg 
cells,  are  down-regulated  during  a  stress-induced  activation 
of the adaptive immune response. Interestingly, however, in 
chronic stress, this scenario might result in an exacerbation 
of  inflammatory  conditions,  such  as  autoimmune  diseases 
(195).
  The potential to therapeutically regulate miRNA levels may 
offer new avenues for cancer treatment and possibly in regu-
lating  the  immune  system.  Inhibiting  oncogenic  miRNAs  or 
reintroduction of tumor suppressor miRNAs may serve as use-
ful strategies to treat cancer. A recent study clearly demon-
strated that reintroduction of tumor suppressor miRNAs can 
cause apoptosis or senescence in malignant cells and provide 
new avenues for development this potential in mouse models 
of  hepatocellular  carcinoma  (200).  Clinical  trials  evaluating 
therapy based on miRNA inhibition or over-expression (42). 
Within the next several years, we will know if miRNA-based 
therapeutics, alone or in combination with other modalities, 
will be clinically useful treatments for various cancers and im-
mune  system  disorders  (42).
POSSIBLE CLINICAL APPLICATION OF miRNAs
A s  m e n t i o n e d ,  m i R N A s  c o n t r o l  v a r i o u s  a c t i v i t i e s  o f  t h e  i m-MicroRNAs in Regulatory T Cells and Immune Response
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mune system and different stage of hemaotopoietic develop-
ment, and their mis-expression is the cause of various blood 
malignancies.  Certain  miRNAs  have  oncogenic  activities, 
whereas others have the potential to act as tumor suppressors 
(35,36,57,60,77), suggesting their  contribution  to  cancer  de-
velopment and progression. Because miRNAs control funda-
mental process such as differentiation, cell growth, and death, 
the study of the role of miRNAs in human neoplasms holds 
great  promise  for  novel  forms  of  therapy  (138).  Therefore, 
miRNA profiling is used to create signature for a variety of 
cancers, indicating that the profile will help further establish 
molecular  diagnosis,  prognosis,  and  therapy  using  miRNA 
(60,77,86,128). miRNA expression profiles can be used to dis-
tinguish normal B-cells in patients with chronic lymphocytic 
leukemia (CLL). A unique miRNA signature is associated with 
prognostic factors and disease progression in CLL (201). Large 
high-throughput  studies  in  patients  revealed  that  miRNA 
profiling has the potential to classify tumors and predict pa-
tient outcome (74). miRNA deficiencies or excess have been 
correlated with a number of clinically important disease rang-
ing from myocardial infarction to cancers (99). Yu et al. in-
vestigated whether miRNA expression profiles can predict the 
clinical  outcome  of NSCLC  (non-small-cell  lung cancer)  pa-
tients (93). They identified a five-miRNA signature for the pre-
diction  of  treatment  outcome  of  NSCLC:  two  miRNAs  (hsa- 
miR-221 and hsa-let-7a) were protective and the other three 
miRNAs (hsa-miR-137, hsa-miR-372, and hsa-miR-182*) were 
risky. They also reported that patients with high-risk scores 
in their miRNA signatures had poor overall and disease-free 
survivals  compared  to  the  low-r i s k - s c o r e  p a t i e n t s ,  a n d  t h a t  
this  miRNA  signature  was  an  independent  predictor  of  the 
cancer relapse and survival of NSCLC patients (93). Multivar-
iate regression analysis showed that the miRNA signature is 
independent from stage or histology and that the miRNA sig-
nature can predict patient survival within cancer stages and 
histological subgroups of NSCLC patients (93). This may have 
prognostic or therapeutic implications for the management of 
NSCLC  patients.
    The potential value of miRNAs as prognostic and predictive 
biomarkers  in  cancer  is  elegantly  highlighted  in  the  recent 
work. Schetter et al. (202) compared miRNA expression pat-
terns in colon adenocarcinoma and adjacent normal tissue us-
ing a test set and validation cohorts. They found that specific 
miRNA signature distinguished colon cancer from normal co-
lon, and a subset of miRNAs was further demonstrated to ex-
hibit  prognostic marker  of poor survival (202).  In addition, 
they  reported  that  high  miR-21  expression  predicted  worse 
survival in treated colon cancer patients and poor responsive-
ness to adjuvant chemotherapy (202). Beyond prognosis and 
prediction, miRNAs associated with neoplastic transformation 
may  mediate  pathophysiological  mechanisms  underlying  tu-
morigenesis (91,203). Waldman and Terzic also reported that 
the role of miRNAs in tumorigenesis underscores their value 
as  a  mechanism-based  therapeutic  target  in  cancer  (90). 
Similarly,  unique  patterns  of  altered  levels  of  miRNA  pro-
duction provide fingerprints that may serve as molecular bio-
markers for tumor diagnosis, classification, prognosis of dis-
ease-specific  outcomes,  and  prediction  of  therapeutic  re-
sponses (90). Many miRNAs with oncogenic activity in hema-
tologic malignancies have been reported. These so-called on-
comirs  such  as  the  miR-17-92  cluster,  miR-21,  and  miR-155 
are often over-expressed in malignant tissues (204). For ex-
ample, the miR-17-92 cluster is a target of genomic amplifica-
tion  13q31  that  occurs  in  Burkitt’s  lymphoma,  diffuse  large 
B - c e l l  l y m p h o m a  ( D L B C L ) ,  m a n t l e  c e l l  l y m p h o m a ,  a n d  f o l-
licular lymphoma (2004). In addition to the miR17-92 cluster, 
miR-155 is one of the oncomirs that has been well charac-
terized in the adaptive immune system in both healthy devel-
opment and malignancy, including B-cell lymphoma, Hodg-
kin’s lymphoma, DLBCL, and Burkitt’s lymphoma. Expression 
of primary miRNA BIC and its derivative miR-155 have been 
demonstrated  in  Hodgkin’s  lymphoma,  primary  mediastinal 
B-cell  lymphoma  (PMBL),  and  DLBCL  (205).
    In contrast to miRNA oncogene function described above, 
other miRNAs function as potent tumor suppressors. The loss 
of such miRNAs is frequently associated with T-cell and B-cell 
lymphoma and leukaemia (206). One example is miR-15a and 
miR-16-1, two miRNAs that are clustered in the 13q14 region. 
In more than 50% of CLL patients, this region is deleted (206). 
Similarly,  miR-29  and  miR-181  are  down-regulated  in  CLL, 
and  have  both  function  as  tumor  suppressors  (207).  These 
miRNAs normally suppress proliferation by targeting pro-sur-
vival  and  pro-proliferation  genes  including  BCL-2,  TCL1, 
MCL1, and CDK6 (206,207). Interestingly, a search for general 
regulators of cancer metastasis has yielded a set of miRNAs 
for which expression is specifically lost as human breast can-
cer  cells  develop  metastatic  potential  (82).  Interestingly, 
Tavazoie et al. showed that restoring the expression of these 
miRNAs in malignant cells suppresses lung and bone meta-
stasis by human cancer cells in vivo (199). Of these miRNAs, 
miR-126  restoration  reduces  overall  tumor  growth  and  pro-
liferation,  whereas miR-335  inhibits metastatic  cell invasion. MicroRNAs in Regulatory T Cells and Immune Response
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Expression of miR-126 and miR-335 is lost in the majority of 
primary breast tumors from patients who relapse, and the loss 
of expression of either miRNA is associated with poor distal 
metastasis-free survival. Thus, miR-335 and miR-126 are meta-
s t a s i s  s u p p r e s s o r  m i R N A s  i n  h u m a n  b r e a s t  c a n c e r  ( 2 0 8 ) .
    As  mentioned,  miRNAs  have  been  implicated  in  several 
carcinogenic process, where they can act either as oncogenes 
or as tumor suppressors (90,204,206). This is the case in lung 
cancer (the leading cause of cancer death in Western coun-
tries), in which about 40-45 miRNAs have been found to be 
aberrantly  expressed,  thereby  constituting  a  specific  miRNA 
signature  (76).  The  different  expression  profiles  of  miRNAs 
in lung cancer, and the stability of miRNA in serum (95), all 
together implicate them as new potentially clinical biomarkers 
for  diagnosis  and  prognosis  (49).  Moreover,  miRNAs  may 
serve as either novel potential targets acting directly as onco-
gene (e.g., miR-17-19 cluster), or directly as therapeutic mole-
cules working as tumor suppressor genes, such as the let-7 
family (49). Some of these miRNAs can play an important role 
in lung carcinogenesis. Changes in the expression profiles of 
miRNAs have been observed in colorectal cancer (CRC) and 
several investigators have also described the ability of miRNAs 
expression  profiles  to  predict  prognosis,  diagnosis,  and  re-
sponse to selected treatments in CRC patients (103). The oc-
currence of miRNAs has been repeatedly observed in serum 
and  plasma,  and  miRNA  as  novel  minimally  invasive  bio-
markers indicate the reasonable sensitivity for CRC detection 
(103).
    Therapeutic strategies based on modulation of miRNA ac-
tivity  hold  great  promise  due  to  the  ability  of  these  small 
RNAs to potently influence cellular behavior. Kota et al. in-
vestigated the efficacy of a miRNA replacement therapy for 
liver cancer (200). They found that hepatocellular carcinoma 
(HCC) cells exhibit reduced expression of miR-26a, a miRNA 
that is normally expressed at high levels in diverse tissues. 
Expression of this miRNA in liver cancer cells in vitro induces 
a G1 cell-cycle arrest associated with direct targeting of cy-
clines D2 and E2 (200). Importantly, they also showed that 
systemic administration of this miRNA in a mouse model of 
HCC using adeno-associated virus (AAV) results in inhibition 
of cancer cell proliferation, induction of tumor-specific apop-
tosis, and dramatic protection from disease progression with-
out toxicity, indicating that AAV-mediated miR-26a delivery is 
very  powerfully  effective.  These  findings  provide  proof-of- 
concept  support  for  systemic  delivery  of  tumor-suppressing 
miRNAs  as  a  powerful  and  highly  specific  anti-cancer  ther-
apeutic  modality  (200).
    More recently, it has been reported that serum and other 
body  fluids  contain  sufficiently  stable  miRNA  signatures 
(62,95,144,146,209). Thus, the profiles of circulating miRNAs 
have been explored in a variety of studies aiming at the iden-
tification of novel non-invasive biomarkers, particularly func-
tions of circulating miRNA in the serum miRNAs are currently 
being extensively explored for their potential as non-invasive 
diagnostic  tumor  markers  (95,144,146,209).  Tumor  specific 
circulating miRNAs may improve cancer diagnosis and prog-
nosis, since several promising miRNAs have already been de-
scribed as non-invasive biomarkers for different tumor entities 
(95).
    As for miRNAs-regulating a change of heart, similar deliv-
ery strategies may enable specific administration of miRNA to 
the heart. miRNAs regulate cardiovascular structure and func-
tion (101). Overexpression of miR-133 blocked cardiac hyper-
trophy in Akt transgenic mice predisposed to left ventricular 
hypertrophy (LVH), whereas wild-type mice developed LVH 
in response to administration of a miR-133 antisense oligonu-
cleotide (ASO) inhibitor. However, LVH was not observed in 
miR-133-deficient mice (101). Clearly, miRNAs play a signifi-
cant role in cardiovascular development and disease. Additio-
nally,  miRNAs  are  important  for  regulating  cardiomyocyte 
self-renewal and differentiation, as well as for normal cardiac 
structural integrity. Results like these in disease models sug-
gest  that  inhibiting  inappropriately  expressed  miRNAs  with 
the use of ASOs and, perhaps replacing missing miRNAs, can 
be used to treat human cardiac disease (101). Identification 
of miRNAs and target genes that contribute to adult cardiac 
pathology is likely to suggest new targets for therapy. Obsta-
cles encountered previously with gene therapy and antisense 
drugs remain an impediment to delivering miRNAs, but pre-
c l i n i c a l  s t u d i e s  f o r  a n t i s e n s e  m i R N A  i n h i b i t o r s  h a v e  b e e n  
promising. Similarly, both preclinical studies and phase II hu-
man trials have been encouraging, suggesting that miRNA re-
placement strategies and miRNA inhibitors will find their way 
into  clinical  use  in  the  not  too  distant  future  (94,101).
  Drug-induced liver injury is a frequent side effects of many 
drugs, constituting a significant threat to patient health, and 
has an enormous economic impact on health care expendi-
tures. The most commonly use diagnostic test for liver injury 
is to determine the activity of certain hepatocelluar enzymes, 
aspartate aminotransferase (AST or SGOT) and alanine amino-
t r a n s e r a s e  ( A L T  o r  S G P T ) ,  i n  t h e  b l o o d .  H o w e v e r ,  t h i s  i n -
formation  is  unreliable  (210).  Numerous  efforts  have  been MicroRNAs in Regulatory T Cells and Immune Response
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made to identify reliable and predictive markers to detect the 
early signs of drug-induced injury to the liver, one of the most 
vulnerable organs in the body. Wang et al. demonstrated that 
specific  miRNA  species,  such  as  miR-122  and  miR-192,  are 
b o t h  e n r i c h e d  i n  t h e  l i v e r  t i s s u e  a n d  p l a s m a  i n  t h e  m o u s e 
a s  m o d e l  s y s t e m . ,  i n d i c a t i n g  t h e  p o t e n t i a l  o f  u s i n g  s p e c i f i c 
circulating miRNA as sensitive and informative biomarkers for 
drug-induced liver injury (106). Recently, discovery of miRNA 
in the body fluids (such as blood, plasma, serum, and saliva), 
has suggested the potential for miRNA-based biomark ers in 
the  detection  of  cardiovascular  diseases  such  as  myocardial 
damage, coronary artery disease (144,145,209), cancer (146, 
148,211-214), and oral disease (147), indicating that miRNA 
may  be  an  excellent  blood-based  biomarker.  These  results, 
although preliminary, strongly suggest that a more compre-
hensive study of circulating miRNAs and their association with 
various physiopathological conditions may lead to another di-
mension in the discovery of biomarkers in the blood for many 
physiological  and  pathological  conditions.  It  has  been  re-
ported  that  lower  complexity,  no  post-processing  mod-
ification,  synthetic  high-affinity  “capsule”  reagent,  tissue-re-
stricted expression profile, and “amplicable” signals make cir-
culating miRNA ideal candidates as biomarkers to reflect vari-
ous  physiopathological  conditions  in  the  body  (210).
CONCLUDING REMARKS
It is becoming clear that miRNA are being identified as key 
regulators of immune cell development and function, as well 
as disease pathogenesis. miRNA signatures have become one 
of the most fascinating interests in current biology and medi-
cal science. Emerging evidence suggests that miRNAs play a 
key role in the regulation of immunological functions includ-
ing innate and adaptive immune responses, development and 
differentiation of immune cells, and the prevention of auto-
immunity.  It  is  also  now  evident  that  aberrant  miRNA  ex-
pression in the immune system is sufficient to cause disease, 
and so proper regulation of miRNA expression seems to be 
crucial  for  disease  prevention.
    To gain functional evidence of the role of miRNA in Treg 
cell biology, several investigators recently have made mouse 
models depleting Dicer specifically in Foxp3 Treg cell line-
age, either using mice with Foxp3Cre knock-in allele (85) or 
using  Foxp3  GFP-hCre  transgenic  mice  (86).  Both  mice 
showed  progression of fatal early onset lymphoproliferative 
autoimmune syndrome indistinguishable from that observed 
in Foxp3 mutant mice devoid of Treg cells. Ablation of either 
Dicer or Drosha results in reduced numbers of Foxp3＋ thy-
mocytes and peripheral Treg cells and immune-mediated le-
sions  developing  at  6-months-of-age.  Dicer  deficient  Treg 
cells showed impaired peripheral homeostasis. Decreased ex-
pression of putative suppressor molecules, including CTLA4, 
ICOS,  IL-10,  EBV-induced  gene  3  (EBi3),  granzyme  B,  and 
CD73  in  Dicer  deficient  Foxp3＋ Treg  cells  has  also  been 
described.
    Treg cells have a miRNA profile distinct from conventional 
CD4 T cells and a partial Treg cell-like miRNA profile is con-
ferred by the enforced expression of Foxp3 and, surprisingly, 
by  the  activation  of  conventional  CD4  T  cells.  Depleting 
miRNAs by eliminating Dicer reduces Treg cell numbers and 
r e s u l t s  i n  i m m u n e  p a t h o l o g y .  D i c e r  f a c i l i t a t e s  t h e  d e v e l o p -
ment of Treg cells in the thymus and the efficient induction 
of Foxp3 by TGF-β. These results suggest that Treg cell de-
velopment  involves  Dicer-generated  RNAs.
    At a mechanistic level, miR-155-mediated control of Treg 
cell homeostasis is mediated through the targeting of SOCS1. 
miR-155 deficiency in Treg cells results in increased SOCS1 
expression  accompanied  by  impaired  activation  of  STAT5 
transcription factor in response to limiting amounts of IL-2. 
  A large number of studies have reported 1) Foxp3 regulates 
miR-155 expression in Treg cells, 2) miR-155 deficiency re-
sults in a reduction of Treg cell numbers, 3) diminished pro-
liferative potential of miR155-deficient Treg cells, 4) miR-155 
maintains competitive fitness of Teg cells, 5) attenuated IL-2 
signaling in miR-155-deficient Treg cells, 6) miR-155 maintains 
Treg cell homeostasis by limiting SOCS1 protein expression; 
SOCS 1 protein amounts are low in miR-155-sufficient Treg 
cells, whereas miR-155-deficient Treg cells exhibit an approx-
i m a t e l y  5 - f o l d  i n c r e a s e  i n  t h e  a m o u n t  o f  S O C S 1  ( 1 5 1 ) .
    More  recently,  a  human  miRNA  Treg  signature  has  been 
explored in healthy volunteers and patients. A variety of hu-
man  miRNA  Treg  signatures  have  been  reported  (186,190, 
192-195). Eight miRNAs are preferentially expressed in nTreg 
(miR-425-Sp,  miR-181c,  miR-21,  miR-374,  miR-586,  miR-340, 
miR-26b,  and  miR-491)  and  two  are  selectively  down-regu-
lated  in  nTReg  (miR-31  and  miR-125a).  This  opens  several 
possibilities for the future, i.e. to qualitatively investigate in-
duced Treg in several circumstances, healthy volunteers, and 
patients  suffering  from  cancer  and  immune  disorders.
    Like miR-155, miR-146a is highly expressed in Treg cells. 
miR-146a  also  modulates  activation-induced  death  domain 
(AICD),  acting  as  an  antiapoptotic  factor  and  that  FADD MicroRNAs in Regulatory T Cells and Immune Response
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(Fas-associated  protein  with  death  domain)  is  a  target  of 
miR-146.
    Experimental findings have revealed new molecular mech-
anisms  through  which  CD4＋CD25＋ T r e g  c e l l s  c o n t a i n  a  
high level of cyclic AMP (cAMP) for their suppressor function. 
O f no t e,  t he  ex p re ssi on  of  m iR -1 4 2- 3 p wa s re ce n tl y sh o wn 
to  be  repressed  by  Foxp3,  leading  to  increased  production 
of  cyclic  AMP  and  suppressor  function  of  Treg  cells.
    As for clinical application of miRNA and Treg cells, certain 
miRNAs have oncogenic activities, whereas others have the 
potential  to  act  as  tumor  suppressor,  suggesting  their  con-
tribution  to  cancer  development  and  progression.  Recent 
studies of the role of miRNAs in human neoplasms hold great 
promise for novel forms of therapy. Therefore, miRNA profil-
ing is used to create signature for a variety of cancers, indicat-
ing that the profile will help further establish molecular diag-
nosis,  prognosis  and  therapy  using  miRNA.
    Large  high-throughput  studies  in  patients  revealed  that 
miRNA profiling has the potential to classify tumors and pre-
dict  patient  outcome.  miRNA  deficiencies  or  excess  have 
been correlated with a number of clinically important disease 
ranging from myocardial infarction to cancers. Multivariate re-
gression  analysis  showed  that  the  miRNA  signature  is  in-
dependent from stage or histology and miRNA signature can 
predict patient survivals within cancer stages and histological 
s u b g r o u p s  o f  N S C L C  p a t i e n t s .  B e y o n d  p r o g n o s i s  a n d  p r e -
diction,  miRNAs  associated  with  neoplastic  transformation 
may  mediate  pathophysiological  mechanisms  underlying 
tumorigenesis.
    As  mentioned,  miRNA  have  been  recently  implicated  in 
several carcinogenic process, where they can act either as on-
cogenes or as tumor suppressors. Therefore, therapeutic strat-
egies  based  on  modulation  of  miRNA  activity  hold  great 
promise  due  to  the  ability  of  these  small  RNAs  to  potently 
influence  cellular  behavior.
    More recently, it has been reported that serum and other 
body fluids contain sufficiently stable miRNA signature. Thus, 
the profiles of circulating miRNAs have been explored in a 
variety of studies aimed at the identification of novel non-in-
vasive biomarkers. Particularly, concerning the functioning of 
circulating  miRNA  in  the  serum,  miRNAs  are  currently  ex-
tensively  explored  for  their  potential  as  non-invasive  diag-
nostic tumor markers. Recent descriptions of miRNA in body 
fluids  (such  as  blood,  plasma,  serum,  and  saliva)  has  sug-
gested the potential for miRNA-based biomarkers in the de-
tection of cardiovascular diseases such as myocardial damage, 
coronary  artery  disease,  cancer  and  oral  disease,  indicating 
that miRNA may be excellent blood-based biomarker. These 
results,  although  preliminary,  strongly  suggest  that  a  more 
comprehensive study of circulating miRNAs and their associa-
tion with various physiopathological conditions may lead to 
another  dimension  in  the  discovery  of  biomarkers  in  the 
blood  for  many  physiological  and  pathological  conditions. 
Currently, there are clinical trials evaluating therapy based on 
miRNA inhibition or over-expression. Within the next several 
years,  we will know if miRNA-based therapeutics, alone or 
in combination with other modalities, will be clinically useful 
treatments for various cancers and immune system disorders. 
  Bases on the body of knowledge from a a large numbers 
of studies, it can be concluded: a) miRNA-155 contributes to 
Treg  cell  development,  2)  miRNA-dependent  regulation  is 
critical  for  preventing  spontaneous  inflammation  and  auto-
immunity, 3) miRNA preserves the Treg cell functional pro-
gram under inflammatory conditions, 4) miRNAs have a cen-
tral role in monitoring the stability of differentiated Treg cell 
function in vivo and in the homeostasis of adaptive immune 
system,  5)  Treg  cell  development  involves  Dicer-generated 
RNAs. Depleting miRNAs by eliminating Dicer, the RNAseIII 
enzyme that generates functional miRNAs, reduces Treg cell 
numbers  and  results  in  immune  pathology.  Dicer  facilitates 
the development of Treg cells in thymus and the efficient in-
duction of Foxp3 by TGF-β, and 6) miRNA can possibly be 
applied  for  diagnosis,  treatment  and  prognosis  for  various 
diseases.
  It is likely that this review is just the tip of the iceberg in 
terms of the involvement of regulatory RNAs in orchestrating 
immune response. It is perhaps not too optimistic to suggest 
that in the future, novel strategies for therapeutic intervention 
in immune related diseases could be based on manipulation 
o f  m i R N A  a n d  T r e g  c e l l s .
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